

An aerial photograph of a park with a large lake in the foreground, surrounded by trees with autumn foliage. In the background, a dense city skyline with various skyscrapers is visible under a clear sky.

Chicago

Fall Group Meeting

OCTOBER 11-14, 2023



A Warm Welcome

Welcome back to Chicago, one of my favorite places on Earth, for another fall group meeting.

This is a particularly exciting time for SWOG! We've already opened ten studies in 2023. Our S2302 Pragmatica-Lung trial is enrolling patients at a prodigious rate and is still generating excitement and serving as a model for the NCTN. S2101, our immunoMATCH pilot study, recently completed stage 1, and the team is working to validate the iMATCH assay before moving to stage 2. MyeloMATCH – the NCI's precision medicine umbrella trial in myeloid malignancies – is headed toward activation, with SWOG leading the core Master Screening and Reassessment Protocol. We've also submitted several outstanding proposals to the NCI's new Clinical Trials Innovation Unit.



These topics are all on the agenda in Chicago, plus much, much more. S2209 in multiple myeloma and S2207 in large B-cell lymphoma hold kickoff sessions. SWOG Clinical Trials Partnerships hosts a Wednesday update forum that will let member sites know what to expect as CTP trials approach activation. Our GI and breast

committees are conducting mini-retreats to plot grant strategy. And we're celebrating 30 years of The Hope Foundation's outsized impact with a plenary and some fun media for exploring the Foundation's history.

As you take advantage of the many opportunities for learning and networking, I urge you to also make time to enjoy Chicago!

Charles D. Blanke, MD
SWOG Chair

Group Meeting Index

Chair's Welcome Message	2
Hotel Maps and Information	4-8
Top Accruers	9
CME Supporters	10
Plenary Sessions	12
Take Action Symposium	13
CME Credit Information	14-15
SWOG Group Meeting App	16
Diversity, Equity and Inclusion Townhall	17
NCORP Research Base Clinical Trials Workshop	18
SWOG Clinical Trials Partnerships (CTP)	19
S2207 and S2209 Kickoff Sessions	20-21
Networking with our Community Advocates	22
Hope Foundation and Future Funding Opportunities	23-24
Schedule of Events	25-29
Nicholas J. Vogelzang, MD, GU Symposium	30
SWOG Administrative and Research Support Committees	31
Future Meeting Dates	31
Committee Agendas and Accrual Reports	
Barlogie-Salmon Myeloma Committee	32-34
Breast Committee	35-41
Cancer Control & Prevention Committee Leadership	42-43
Cancer Care Delivery Committee	44-48
Cancer Survivorship Committee	49-50
Early Therapeutics & Rare Cancers Committee	59-62
Gastrointestinal Committee	63-70
Genitourinary Committee	71-82
Immunotherapeutics Committee	83
Leukemia Committee	84-86
Lung Committee	88-97
Lymphoma Committee	98-101
Melanoma Committee	102-105
Palliative & End of Life Care Committee	51-52
Prevention & Epidemiology Committee	53-55
Radiation Oncology Committee	106-107
Symptom Control & Quality of Life Committee	56-58
SWOG Publications	108-117

Hyatt Regency Chicago Floor Levels



WELCOME TO HYATT REGENCY CHICAGO.

Meeting rooms, ballrooms, restaurants and guest amenities are listed in alphabetical order and color coded by floor. For help, dial Guest Services at Extension **4460**.

ESCALATORS, ELEVATORS AND RESTROOMS

are indicated on each floor. Elevators are conveniently located throughout the hotel for guests with disabilities or where no escalator is present.

CROSSING BETWEEN


TOWERS: Cross between towers via the Skybridge or the Concourse. You may also cross from the lobby level via the crosswalk on Stetson Drive.

151 East Wacker Drive
Chicago, Illinois 60601, USA
hyattregencychicago.com
Phone: +1.312.565.1234
Fax: +1.312.239.4541

ACAPULCO (<i>International and City Suites</i>) West Tower, Ballroom Level	HONG KONG (<i>International and City Suites</i>) West Tower, Ballroom Level
ADDAMS (<i>Founders Suites</i>) West Tower, Third Floor	HORNER (<i>Founders Suites</i>) West Tower, Third Floor
AMERICAN CRAFT KITCHEN & BAR East Tower, Lobby Level	THE LIVING ROOM West Tower, Skyway Level
ATLANTA (<i>International and City Suites</i>) West Tower, Ballroom Level	MARKET CHICAGO East Tower, Lobby Level
BELL DESK East Tower, Skyway Level	MCCORMICK (<i>Founders Suites</i>) West Tower, Third Floor
BIG BAR East Tower, Skyway Level	MICHIGAN (<i>Lakeshore Meeting Rooms</i>) East Tower, Concourse Level
BURNHAM (<i>Founders Suites</i>) West Tower, Third Floor	MONROE (<i>Lakeshore Meeting Rooms</i>) East Tower, Concourse Level
BUSINESS CENTER, PACKAGE ROOM East Tower, Exhibit Level	NEW ORLEANS (<i>International and City Suites</i>) West Tower, Ballroom Level
COLUMBIAN (<i>Landmark Suites</i>) West Tower, Concourse Level	OGDEN (<i>Founders Suites</i>) West Tower, Third Floor
COLUMBUS HALL (ROOMS A-L) East Tower, Ballroom Level	PICASSO (<i>Landmark Suites</i>) West Tower, Concourse Level
COMISKEY (<i>Landmark Suites</i>) West Tower, Concourse Level	PLAZA BALLROOM East Tower, Lobby Level
CONCIERGE East Tower, Lobby Level	RANDOLPH (<i>Lakeshore Meeting Rooms</i>) East Tower, Concourse Level
CRYSTAL BALLROOM West Tower, Lobby Level	REGENCY BALLROOM West Tower, Ballroom Level
DUSABLE (<i>Founders Suites</i>) West Tower, Third Floor	RIVERSIDE CENTER East Tower, Exhibit Level
EAST TOWER MAIN ENTRANCE East Tower, Lobby Level	ROOSEVELT (<i>Lakeshore Meeting Rooms</i>) East Tower, Concourse Level
EAST TOWER VALET East Tower, Ballroom Level	SAN FRANCISCO (<i>International and City Suites</i>) West Tower, Ballroom Level
FIELD (<i>Founders Suites</i>) West Tower, Third Floor	SANDBURG (<i>Founders Suites</i>) West Tower, Third Floor
FITNESS CENTER West Tower, Skyway Level	SKYWAY MEETING ROOMS East Tower, Skyway Level
FRONT DESK East Tower, Skyway Level	SOLDIER FIELD (<i>Landmark Suites</i>) West Tower, Concourse Level
THE GALLERY COLLECTION West Tower, Skyway Level	STETSON CONFERENCE CENTER West Tower, Exhibit Level
GIFT SHOP East Tower, Concourse Level	STETSONS MODERN STEAK + SUSHI East Tower, Lobby Level
GOLD COAST (<i>Landmark Suites</i>) West Tower, Concourse Level	TORONTO (<i>International and City Suites</i>) West Tower, Ballroom Level
GRAND BALLROOM East Tower, Ballroom Level	WATER TOWER (<i>Landmark Suites</i>) West Tower, Concourse Level
GRAND SUITES East Tower, Ballroom Level	WEST TOWER VALET West Tower, Exhibit Level
HAYMARKET (<i>Landmark Suites</i>) West Tower, Concourse Level	WRIGHT (<i>Founders Suites</i>) West Tower, Third Floor
HERTZ East Tower, Lobby Level	WRIGLEY (<i>Landmark Suites</i>) West Tower, Concourse Level

Chicago Travel & Hotel Information

151 East Wacker Drive | Chicago, Illinois 60601, USA
 hyattregencychicago.com | Phone: 312 565 1234 | Fax: 312 239 4541



Chicago Travel & Hotel Information

151 East Wacker Drive | Chicago, Illinois 60601, USA
 hyattregencychicago.com | Phone: 312 565 1234 | Fax: 312 239 4541



Arrival/Departure:

Check-in time is 3:00 p.m. Check-out time is 12:00 noon. Room amenities include a full bath, hair dryer, ironing board and iron. The concierge staff serves as a liaison between guests and the hotel and outside services.

Hotel Safety Deposit Boxes:

For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

Recreational Facilities:

The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. It is open 24 hours a day.

Hotel Restaurants and Lounges:

Stetsons Modern Steak & Sushi: Non-traditional steakhouse experience in a comfortable urban setting, specializing in steaks and seafood. *Restaurant is open daily at 5:00 p.m.*

American Craft Kitchen & Bar: Regionally inspired by all corners of the country, they offer an approachable dining experience with handcrafted food and drink. This atrium restaurant is the perfect stop for a casual meal. *Open daily from 6:30 a.m. – 11:00 p.m.*

Market Chicago: Offers breakfast, lunch or dinner for a quick meal or coffee to go. *Open daily from 6:30 a.m. – 11:30 p.m.*

The BIG Bar features the longest free-standing bar in North America and specializes in a wide variety of cocktails, wines, champagnes and cognacs and snacks. *Open daily at 4:00 p.m.*

In-room dining is available from 6:00 a.m. - 12:00 a.m. *daily.*

Chicago Travel & Hotel Information

151 East Wacker Drive | Chicago, Illinois 60601, USA
 hyattregencychicago.com | Phone: 312 565 1234 | Fax: 312 239 4541

Business Center:

The Business Center is located on the Exhibit level in the East Tower of the hotel. It is open 24 hours a day, 7 days a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access and photocopying.

Ground Transportation:

- A taxi ride from O'Hare airport to the hotel is approximately **\$52.00 one-way**.
- A taxi ride from Midway airport to the hotel is approximately **\$35.00 one-way**.
- Valet parking at the hotel is **\$79.00 per day** for hotel guests.

Temperature:

The average high for October is 64 degrees and the average low is 46 degrees.

Area Attractions:

- Adler Planetarium and Astronomy Museum
- Architectural Boat Tours
- Art Institute of Chicago
- Brookfield Zoo
- Buckingham Fountain
- Chicago Architecture Foundation
- Chicago Botanic Garden
- Field Museum of National History
- John G. Shedd Aquarium
- John Hancock Center Observatory
- Lincoln Park Zoo and Conservatory
- Maggie Daley Park
- Millennium Park and Cloud Gate ("The Bean")
- Museum of Contemporary Art
- Museum of Science and Industry
- Navy Pier
- Rockefeller Memorial Chapel
- Willis Tower Skydeck



Hyatt Regency Chicago Restaurant Guide

DINING ON-SITE

BIG BAR

East Tower, Skyway Level

AMERICAN CRAFT KITCHEN & BAR

East Tower, Lobby Level

MARKET CHICAGO

East Tower, Lobby Level

LOCAL FAVORITES

BILLY GOAT TAVERN

American, \$

430 N. Michigan Ave. • 312.222.1525

.1 miles from hotel

GARRETT POPCORN SHOPS

Gourmet Popcorn, \$

4 E. Madison St. • 888.476.7267

.7 miles from hotel

GIORDANO'S

Pizza, \$\$

130 E. Randolph St. • 312.616.1200

.2 miles from hotel

LOU MALNATI'S

Pizza, \$\$

439 N. Wells St. • 312.828.9800

.9 miles from hotel

PORTILLO'S HOT DOGS

Quick Service, \$

100 W. Ontario St. • 312.587.8910

.9 miles from hotel

STAN'S DONUTS & COFFEE

Gourmet Donuts, \$

181 Michigan Ave. • 312.729.5480

.3 miles from hotel

NEARBY DINING

BEATRIX

American, \$\$

519 N. Clark St. • 312.284.1377

1 mile from hotel

BROKEN ENGLISH TACO PUB

Mexican, \$\$

75 E. Lake St. • 312.929.3601

.4 miles from hotel

THE DEARBORN

American, \$\$

145 N. Dearborn • 312.384.1242

.7 miles from hotel

GIBSONS BAR & STEAKHOUSE

Steakhouse, \$\$\$

1028 N. Rush St. • 312.266.8999

1.2 miles from hotel

ITALIAN VILLAGE

Italian, \$\$

71 W. Monroe St. • 312.332.7005

1 mile from hotel

JOE'S SEAFOOD

Seafood, Steakhouse, \$\$\$

60 E. Grand Ave. • 312.379.5637

.7 miles from hotel

MAGNOLIA BAKERY

Coffee, Dessert, \$\$

108 N. State Street. • 312.346.7777

.7 miles from hotel

NANDO'S PERI-PERI

Portuguese, Quick Service, \$\$

117 E. Lake St. • 312.729.5340

.2 miles from hotel

NUTELLA CAFE

Cafe, Coffee Bar, \$\$

189 N. Michigan Ave. • 800.861.4888

.2 miles from hotel

POTBELLY SANDWICH SHOP

Sandwiches, Quick Service, \$

111 E. Wacker Dr. • 312.861.0013

.1 miles from hotel

PURPLE PIG

Mediterranean, \$\$

500 N. MI Ave • 312.464.1744

.9 miles from hotel

QUARTINO RISTORANTE

Italian, \$\$

626 N. State St. • 312.337.9400

.8 miles from hotel

RAMEN-SAN

Japanese, Sushi, \$\$

59 W. Hubbard St. #2 • 312.377.9950

.9 miles from hotel

ROTI

Mediterranean, Quick Service, \$

80 E. Lake St. • 312.858.8190

.3 miles from hotel

RPM ITALIAN

Italian, \$\$\$

52 W. Illinois St. • 312.222.1888

.7 miles from hotel

SHAKE SHACK

American, Quick Service, \$\$

12 S. Michigan Ave. • 312.646.6005

.5 miles from hotel

SWEETWATER TAVERN & GRILLE

American, Pub, \$\$

225 N. Michigan Ave. • 312.698.7111

.3 miles from hotel

WILDBERRY PANCAKES & CAFE

Breakfast & Lunch, \$\$

130 E. Randolph St. • 312.938.9777

.2 miles from hotel

YOLK

Brunch, Cafe, \$\$

355 E. Ohio St. • 312.822.9655

.6 miles from hotel



Our Top Accruers

Patient volunteers power our trials — and SWOG members connect us to them.

These members led in SWOG-credited registrations to SWOG-managed trials January 1 to June 30, 2023.



- University of Colorado Cancer Center
- Lahey Hospital and Medical Center
 - University of Michigan Comprehensive Cancer Center
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC)
 - USC Norris Comprehensive Cancer Center



- Heartland Cancer Research NCORP
- University of Kansas Cancer Center – MCA Rural MU NCORP
- Kaiser Permanente NCI Community Oncology Research Program
- Carle Cancer Center NCI Community Oncology Research Program
- Cancer Research of Wisconsin and Northern Michigan Consortium



We Value Our Meeting Partners – Thank You!
Activities supported by independent
medical education grants from:

Lilly

Novartis

AbbVie

Exact Sciences

Regeneron
Pharmaceuticals, Inc.

Novocure

Takeda

The Hybrid Meeting, Fall 2023

Welcome to SWOG's Fall 2023 Hybrid Group Meeting!



Most open meeting sessions held in person in Chicago will also be accessible everywhere via Zoom.

Zoom links to open meetings are posted on the virtual meeting page on the SWOG website. Zoom links to closed, invitation-only meetings are emailed directly to those invited.

Each room will have a presentation laptop with a projector and screen. Virtual presentations by remote presenters will be visible on the projector screen to those in the room.

All presenters will have their slides displayed in the Zoom meeting interface. Virtual attendees will view them via Zoom, while in-person attendees will view them on the projector screen.

Audio will be two way as needed. For virtual presenters, the Zoom audio will be amplified for the room. For in-room speakers, audio from microphones will be fed into Zoom.

For many sessions, virtual attendees can post questions for the presenters using the Zoom chat feature. In these sessions, a moderator will usually monitor the chat.



Most hybrid sessions will be recorded, and recordings from open sessions will be available to attendees after the meeting.

Get the Scoop!

Want the Front Line blog every Friday?

Or the Translational Medicine Link of the Week?

How about the Hope Foundation Monthly E-Newsletter?



Email communications@swog.org to get on a list – one or all three

Plenary I

Thursday, October 12, 3:30 – 5 pm CT • Regency B-D (Ballroom Level, West Tower)

This fall's translational medicine plenary will feature the following speakers and topics:



Welcome and Introduction

Lee M. Ellis, MD, FASCO
SWOG Vice-Chair for Translational Medicine
MD Anderson Cancer Center



S2108CD: Implementing Genomic Tumor Boards in the Community Setting: Can We Increase Evidence-Based Genome-Informed Therapy?

Jens Rueter, MD
The Jackson Laboratory



TM Efforts of the DART Trial: Building the Rare Tumor TCGA

Young Kwang Chae, MD, MPH, MBA
Northwestern University
Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center




Keynote – Cancer Immune Monitoring and Analysis Centers (CIMACs)

SWOG and CIMAC Collaborations: A Challenging, But Successful, Journey

Ignacio I. Wistuba, MD
MD Anderson Cancer Center

Panel discussion with Q&A will follow.



NCTN CIMAC: Curing Cancer by Working Together

Helen X. Chen, MD
Cancer Therapy and Evaluation Program, National Cancer Institute

Attendees can earn Continuing Medical Education (CME) credits for this event.

Plenary II

Many Generations of Hope • Friday, October 13, 12:00 – 2:00 pm CT • Regency B-D (Ballroom Level, West Tower)

This fall's general plenary will feature the following speakers and topics. We will celebrate 30 years of impact of The Hope Foundation for Cancer Research.



Chair's Welcome and Update

Charles D. Blanke, MD, FASCO, FAWM
SWOG Group Chair
OHSU Knight Cancer Institute



Hope Support and the S1820 Trial

Virginia Sun, PhD, MSN, RN
Professor, Department of Population Sciences and Department of Surgery
City of Hope



Reengaging Veterans Affairs Medical Centers and Bringing NCTN Trials to More Veterans

Stephen D. Bartlett, RPh, MSPH
Assistant Professor
University of Colorado Anschutz
Rocky Mountain Regional VA Medical Center



Moving SWOG to a More Diverse, Equitable, and Inclusive Future

Patricia Robinson, MD
Professor of Medicine
Loyola University Medical Center



The Hope Foundation for Cancer Research at 30: A Generation of Impact

Jo Horn
President and CEO
The Hope Foundation for Cancer Research

Each presentation will be followed by a brief opportunity for audience members to pose questions to the speaker. Moderator: Charles D. Blanke, MD

Attendees can earn Continuing Medical Education (CME) credits for this event.

TAKE ACTION SYMPOSIUM:

Enhancing Community Engagement in Clinical Research

presented by SWOG Recruitment & Retention Committee

WEDNESDAY, OCTOBER 11 • 3:30 - 5:30 PM • REGENCY D (BALLROOM LEVEL, WEST TOWER)

Target Audience: Investigators, research professionals, and patient advocates

OBJECTIVES

1 *Understanding your community and building trust*

2 *Normalizing clinical trials as the best treatment option*

3 *Meaningfully engaging underserved and underrepresented patients*

4 *Identifying evidenced based practical strategies for community engagement*

PANELISTS & MODERATORS

10 min.

Introduction:

Take Action Series:
Panelists & Moderators



Allison Caban-Holt, PhD
Moderator



Kamara Mertz-Rivera,
MA, CCRC

20 min.

Community Engagement: Why is it important to engage underrepresented populations?



Lynne Nguyen,
MPH

20 min.

Digital Approaches to Enhancing Community Engagement



Mark Lewis, MD

20 min.

Community Engagement – Practical Approaches



Audrianna Carrington, MS

30 min.

Q&A: All Speakers & Panelists

15 min.

Wrap-Up: Allison Caban-Holt, PhD

CME:

Continuing education credit will be available.

Procedures for CME Credit

Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists, and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following sessions: Adolescent and Young Adult Committee; Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control & Quality of Life Committee, Prevention & Epidemiology Committee, Palliative & End of Life Care Committee, and Cancer Survivorship Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee; Lymphoma Committee; Immunotherapeutics Committee; Digital Engagement Committee; Bone Marrow & Stem Cell Transplantation Committee; Recruitment and Retention Committee; and Advanced Practice Providers.

Continuing Medical Education Credit

The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. In addition, nurses, CRAs, and other researchers may be able to claim credits through their respective credentialing bodies.

The Hope Foundation designates this live activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Learners should only claim credit commensurate with the extent of their participation in the activity.

Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Best attempts will also be made to provide up to date information on introductory slides at each CME session.

Our CME credit system has moved to the Conference Exchange (Confex) meeting app!

To claim credit, you must create a **Confex user account**. You may use the account to navigate the meeting through the mobile app — or alternatively, via the browser-based version online.

To download the meeting app, find it in the Apple Store or via Google Play:



To navigate the meeting and claim CME credit online, go here: swog.org/meetingappF23

1
Use the **Meeting Calendar** or **Search** options to navigate to the session you attended and click on the session title.

2
Claim CME Credit
Click on the **Claim CME** button and complete the form for the session. Repeat this process for each session that you attended.

3
If a **Claim CME** button does not appear on the page, the session was not approved to offer CME credit.

4
At the conclusion of the group meeting, you will need to complete the **CME Meeting Evaluation**, which is linked from the **Claim CME Credit** page.

5
Once you have submitted the CME Meeting Evaluation, click the **Review Credit Hours and Certificates** link on the **Claim CME Credit** page to view and print your certificate(s).

Update Personal Information

Credits Evaluation List for Courtney Wille

Overall Certificates

Sent **Attendee Certificate - PDF**

Sent **Credit Transcript - PDF**

Wednesday, October 11, 2023

Digital Engagemant Committee [CME]

Max Credit Allowed: 2.00
October 11, 2023 2:30 PM - 2:30 PM
Regency B (Hyatt Regency Chicago)

Credit Claimed: 2.00

Instructions

Enter Email Address **Send Certificate(s)**

The deadline for claiming credit hours is December 14th at 11:59pm CST

SWOG Group Meeting App

The new SWOG group meeting mobile app is your pocket guide to the meeting.

With key features in an easily accessible format, the app not only replaces the agenda book as your on-site companion, it contains the agenda book – as a PDF you can flip through on your phone.

WITH THE APP, YOU CAN

1 create your schedule, annotate sessions, and add them to your calendar

3 claim continuing medical education (CME) credits for sessions you attend

2 access a directory of presenters and session leaders, along with other attendees who have opted in

The app also offers a single go-to source for speakers and presenters:

4 access most of the key resources you've found in the agenda book

- find travel and lodging information and links
- submit conflict-of-interest disclosure forms
- upload slides and handouts for your talk

5 access the full agenda book itself as a PDF



swog.org/appleappF23



swog.org/googleappF23

DON'T HAVE THE APP YET?

Download the app with the appropriate QR code or URL at left

DON'T WANT TO INSTALL YET ANOTHER APP?

Access the web browser version with the QR code or URL at right.



swog.org/meetingappF23

Swipe up to open

THURSDAY, OCT. 12, 2 - 3 PM CT • CRYSTAL A (LOBBY LEVEL, WEST TOWER)

DIVERSITY, EQUITY, AND INCLUSION

TOWN HALL



Opening remarks by

Christopher N. Cross, PhD

Director, Health Equity Strategies

Center for Equity, Diversity and Inclusion

American Society of Clinical Oncology

The Town Hall will be an opportunity to hear about our efforts in DEI in SWOG and why it is important to the work we do and the communities we are building. It will offer all a chance to meet those leading these efforts and more importantly, to ask questions and have your voice heard. Our efforts must take in to account all of our views in a way that moves us forward with intentionality utilizing an iterative approach of learning from each other on both, what has worked and what has not.

All are invited!

WEDNESDAY, OCTOBER 11 • 11:30 AM - 3:30 PM CT

NCORP Research Base Clinical Trials Workshop

SWOG members, clinical research professionals, and investigators at NCTN and NCORP institutions are encouraged to attend the informative presentations and breakout session discussions.

The workshop provides information on conducting clinical trials in the following five SWOG committees:

Cancer Care
Delivery



Cancer
Survivorship



Palliative
and End of
Life Care



Prevention and
Epidemiology



Symptom
Control and
Quality of Life



Dr. Dawn Hershman, SWOG group co-chair-elect, serves as SWOG vice chair for NCI Community Oncology Research Program (NCORP) research.

This is an opportunity for information sharing between attendees, SWOG NCORP research staff, study chairs, the NCI, and other subject matter experts.

Society of Clinical Research Associates (SOCRA) continuing education credit is available.

WED, OCT 11, 11:30 AM – 12:30 PM CT • REGENCY A (BALLROOM LEVEL, WEST TOWER)

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum *Behind the Scenes and on Stage*

ATTEND TO LEARN ABOUT ...

- The CTP process: from a joint SWOG Committee/Industry Partner “idea” to protocol activation
- Several SWOG CTP projects, fully industry funded, now nearing final stages of contracting and development

21CTP.GU01

Phase II study in first-line muscle-invasive bladder cancer with multiple arms of neoadjuvant therapy defined by molecular subtype

21CTP.HN01

Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies

21CTP.LEUK01

Phase II trial for patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia

- Other projects SWOG CTP has in development
- What SWOG sites can expect for SWOG CTP trials
 - Study feasibility and site selection process
 - Site funding and contracts
 - CTP systems – EDC, eISF, IRB

All are invited!

SWOG CLINICAL TRIALS PARTNERSHIPS

AN LLC OF THE HOPE FOUNDATION FOR CANCER RESEARCH

For more information, visit

swogctp.org

Email us at CTP@swog.org

TROPION-Breast03

In another model, SWOG CTP provides scientific leadership and is lead academic group for this global AstraZeneca-sponsored registration trial. Over 40 SWOG sites selected and in process of activation or are enrolling.

THURSDAY, OCTOBER 12, 1 – 2:30 PM CT • PLAZA A (LOBBY LEVEL, EAST TOWER)

S2207

The **S2207** kickoff session will provide valuable information to SWOG members who will be enrolling patients to this new trial in large B-cell lymphoma. Join us in person in Chicago or virtually from anywhere.

S2207: Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

STUDY CHAIRS



Jennifer Amengual, MD




Patrick Reagan, MD



Sonali Smith, MD



Alexey Danilov, MD (TM)

Hayder Saeed, MD
(PROs)

S2207 was activated at the end of June. It will enroll patients with large B-cell lymphoma (LBCL) who are considered ineligible for transplant or for CAR T-cell therapy or who have relapsed after these treatments.

This three-arm randomized trial compares a tafasitamab-lenalidomide combination alone to the combination plus tazemetostat or plus zuberutinib.

This S2207 kickoff session will review

- trial background, eligibility criteria, and the treatment plan
 - biospecimen collection
 - patient-reported outcomes
 - patient education materials

The trial's target patient population is treated primarily in the community setting.

Staff at community treatment centers are encouraged to attend.

Our patient advocates have been working with the study team to craft additional patient education materials for the trial. We will share printed copies of these at the S2207 kickoff session.

BRING YOUR QUESTIONS!


THURSDAY, OCTOBER 12, 7:30 – 8:30 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

S2209

Recently activated **S2209** is SWOG’s high-priority phase III trial for patients newly diagnosed with multiple myeloma who are not candidates for transplant. Members at sites opening (or considering opening) the trial should plan to attend the **S2209 kickoff session**.

S2209: A Phase III Randomized Trial for “Frail” or a Subset of “Intermediate Fit” Newly Diagnosed Multiple Myeloma (NDMM) Patients Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

STUDY CHAIRS



Sikander Ailawadhi, MD



Jing Christine Ye, MD, MS




Brea Lipe, MD



Kristina Gowin, DO (QOL/PRO)



Thomas Chauncey, MD, PhD (VA Cmte)



This three-arm trial aims to meet unmet needs in frail and other real-world patients with NDMM. It’s designed to maximize enrollment among patients often excluded from prospective clinical trials.

Trial objectives include comparisons of patient-reported quality-of-life outcomes and comparisons of rates of minimal residual disease (MRD).

A smooth launch of this trial requires careful coordination of its multiple components. This kickoff meeting will provide critical support to sites getting ready to enroll patients to S2209.


COME AND HAVE YOUR QUESTIONS ANSWERED!



A Networking Event with AYA and LGBTQ+ Community Advocates

Want to talk about the LGBTQ+ community within SWOG?
Or grow the AYA community?

Calling all members of these communities, allies, and those with questions.



JOËL POINTON, MPH
LGBTQ+ Community Advocate
AND
LAUREN FRYZEL
AYA Community Advocate



**WE WOULD LOVE TO TALK ABOUT OUR COMMUNITIES AND
THE COMMUNITY ADVOCATES INITIATIVE AT SWOG!**

**Come talk, and help us build a
VILLAGE OF COMMUNITIES
within SWOG!**

Join us for conversation and networking, over drinks and refreshments, on

Thursday, October 12,
5 - 6:30 pm CT at the

American Craft Lounge Area
(in front of the American Craft Restaurant, Lobby Level, East Tower -- look for this sign!)

Give a gift to support your group today – help us honor a generation of impact.

The Hope Foundation partners with SWOG to fund research grants, fellowships, training events, physician education, patient advocacy, and critical infrastructure needs.



 SCAN ME



Learn more at
thehopefoundation.org/donate



THE
HOPE
FOUNDATION
A GENERATION OF IMPACT

Future Funding Opportunities

- SEED Fund Program: **December 1**
- Impact Award Program: **January 15 (LOI)**
- Dr. Charles A. Coltman, Jr. Fellowship: **March 1**
- Career Engagement Award: **March 1**

 SCAN ME



Visit thehopefoundation.org

[THEHOPEFOUNDATION.ORG/FUNDING-OPPORTUNITIES](https://thehopefoundation.org/funding-opportunities)

READ THE STORIES
THAT SHAPED OUR HISTORY



LEFT TO RIGHT
John Crowley, PhD,
Jo Horn, Cathy Tangen, DrPH

1993 On April 24, 1993 in
Denver, the Southwest

Oncology Group board of governors
elected the first board of directors
for the Southwest Oncology Group
Foundation, a group that included
Dr. John Crowley.

The generation of
Hope had begun.

2023 Through thirty years
of supporting SWOG,
we've helped launch careers and
clinical trials, empowered new
committees and working groups, sent
hundreds of investigators, nurses, and
advocates to professional trainings
and collaborative meetings.


We've helped drive
progress.

At the group meeting
in Chicago?

Visit our staff near SWOG meeting
registration to learn more about our
mission and our 30-year history supporting
SWOG and its members.

And Friday's general plenary session will
celebrate 30 years of impact - don't miss
these special presentations!

LISTEN TO THE VOICES OF OUR
LEADERS AND GRANTEES



VISIT OUR TIMELINE & HISTORY
THROUGH THE YEARS



Schedule of Events

WEDNESDAY, OCTOBER 11, 2023

Group Meeting Registration & Information Desk
8:00 am - 5:00 pm: Regency Foyer, Ballroom Level, West Tower

**Unless otherwise indicated, all meetings are located in the West Tower of the hotel.*

8:30 AM-11:30 AM

Toronto (Ballroom Level)

Advocates Committee (Invitation Only)

9:30 AM-11:00 AM

Soldier Field (Concourse Level)

Quality Initiative Meeting (Invitation Only)

11:00 AM-11:30 AM

Regency D Foyer (Ballroom Level)

NCORP Workshop Check-In

11:30 AM-3:30 PM

Regency D (Ballroom Level)

SWOG NCORP Research Base Clinical Trials Workshop

11:30 AM-12:30 PM

Soldier Field (Concourse Level)

ORP Oishi/Open Forum Working Meeting (Invitation Only)

11:30 AM-12:30 PM

Regency A (Ballroom Level)

Clinical Trials Partnerships Update Forum

12:30 PM-2:00 PM

Acapulco (Ballroom Level)

Core Office Staff Meeting (Invitation Only)

12:30 PM-2:30 PM

Regency B (Ballroom Level)

Digital Engagement Committee [CME]

1:00 PM-4:00 PM

Toronto (Ballroom Level)

Breast Committee Retreat (Invitation Only; In Person Only)

2:00 PM-3:30 PM

San Francisco (Ballroom Level)

SWOG Tissue Banking Meeting (Invitation Only)

2:30 PM-4:30 PM

Soldier Field (Concourse Level)

VA Program Development Team Strategic Planning Meeting (Invitation Only)

3:30 PM-5:00 PM

Haymarket (Concourse Level)

Hope Foundation Board Meeting (Board Members Only)

3:30 PM-5:30 PM

Regency D (Ballroom Level)

Take Action Symposium presented by the SWOG Recruitment and Retention Committee [CME]

4:00 PM-6:00 PM

Regency B (Ballroom Level)

Adolescent and Young Adult (AYA) Committee [CME]

4:15 PM-5:30 PM

San Francisco (Ballroom Level)

Nursing Research Subcommittee (Invitation Only)

5:30 PM-7:30 PM

Regency A (Ballroom Level)

Site Operations

5:30 PM-8:00 PM

Acapulco (Ballroom Level)

NCORP Research Base Executive Committee Meeting (Invitation Only)

Schedule of Events

THURSDAY, OCTOBER 12, 2023

Group Meeting Registration & Information Desk
7:00 am - 5:00 pm: Regency Foyer, Ballroom Level, West Tower

Hope Foundation Information Desk
8:00 am - 5:00 pm: Regency Foyer, Ballroom Level, West Tower

Exhibits & Complimentary Coffee Service
8:00 am - 5:00 pm: Toronto, Ballroom Level, West Tower

**Unless otherwise indicated, all meetings are in the West Tower of the hotel.*

7:30 AM-8:00 AM

Regency B Foyer (Ballroom Level) *Jeri & Noboru Oishi Symposium Check-In*

8:00 AM-11:00 AM

Regency BC (Ballroom level) *Jeri & Noboru Oishi Symposium*

8:00 AM-10:00 AM

Regency A (Ballroom Level) *Cancer Care Delivery Committee [CME]*

8:00 AM-10:00 AM

Acapulco (Ballroom Level) *Lung-MAP Administrative Meeting (Invitation Only)*

10:00 AM-12:15 PM

Regency D (Ballroom Level) *Early Therapeutics and Rare Cancers Committee [CME]*

10:15 AM-12:15 PM

Regency A (Ballroom Level) *Palliative and End of Life Care Committee [CME]*

10:15 AM-12:45 PM

Comiskey (Concourse Level) *Breast Translational Medicine Working Group (Invitation Only)*

11:00 AM-1:00 PM

Crystal A (Lobby Level) *SWOG Latin America Initiative Symposium*

12:00 PM-2:00 PM

Plaza B (Lobby Level, East Tower) *Lung-MAP Site Coordinators Committee Meeting (Invitation Only)*

12:00 PM-3:00 PM

Acapulco (Ballroom Level) *Myeloma Working Group (Invitation Only)*

12:30 PM-2:00 PM

Crystal B (Lobby Level) *ORP Open Forum (In person only)*

12:30 PM-2:30 PM

San Francisco (Ballroom Level) *Sarcoma Working Group of the ETxRC Committee*

12:30 PM-2:30 PM

Regency A (Ballroom Level) *Prevention and Epidemiology Committee [CME]*

1:00 PM-2:00 PM

Soldier Field (Concourse Level) *Clinical Trials Partnerships Scientific Advisory Board (Invitation Only)*

1:00 PM-2:30 PM

Plaza A (Lobby Level, East Tower) *S2207 Kick-Off Meeting*

1:00 PM-3:00 PM

Crystal C (Lobby Level) *Immunotherapeutics Committee [CME]*

2:00 PM-3:00 PM

Crystal A (Lobby Level) *Diversity, Equity, and Inclusion Townhall*

2:30 PM-3:30 PM

Regency Foyer (Ballroom Level) *Plenary Reception (Light Hors d'Oeuvres)*

3:30 PM-4:30 PM

Soldier Field (Concourse Level) *DEI Leadership Council*

3:30 PM-5:00 PM

Regency B-D (Ballroom Level) *Plenary I (Translational Medicine) [CME]*

Schedule of Events

3:30 PM-5:00 PM

San Francisco (Ballroom Level) *APP Task Force (Invitation Only)*

5:00 PM-6:30 PM

American Craft Lounge (Lobby Level, East Tower) *Networking with Our Community Advocates*

5:15 PM-7:00 PM

Comiskey (Concourse Level) *Lung Radiation/Surgery Subcommittee (Invitation Only)*

5:15 PM-7:15 PM

Crystal A (Lobby Level) *VA Committee*

5:15 PM-7:15 PM

Crystal C (Lobby Level) *CNS Working Group*

5:15 PM-7:15 PM

Regency A (Ballroom Level) *Cancer Survivorship Committee [CME]*

5:15 PM-7:15 PM

Soldier Field (Concourse Level) *Conflict Management Committee (Invitation Only)*

5:15 PM-7:15 PM

Acapulco (Ballroom Level) *Lymphoma Working Group (Invitation Only; In Person Only)*


6:00 PM – 8:00 PM

Plaza B (Lobby Level, East Tower) *Early Therapeutics Working Group (Invitation Only; In Person Only)*

7:30 PM-8:30 PM

Comiskey (Concourse Level) *S2209 Kick off Meeting*

Tweeting the Meeting



Twitter, X, ... whatever you choose to call it, it remains a great place to share your group meeting highlights.

Tag @SWOG when you share, and we can amplify!

Follow SWOG at
twitter.com/SWOG

When you tweet from the group meeting ... don't forget to use

#SWOGonc

Schedule of Events

FRIDAY, OCTOBER 13, 2023

Group Meeting Registration & Information Desk
6:30 am - 5:00 pm: Regency Foyer, Ballroom Level, West Tower

Hope Foundation Information Desk
8:00 am - 5:00 pm: Regency Foyer, Ballroom Level, West Tower

Exhibits & Complimentary Coffee Service
8:00 am - 5:00 pm: Toronto, Ballroom Level, West Tower

**Unless otherwise indicated, all meetings are in the West Tower of the hotel.*

7:00 AM-9:00 AM

Soldier Field (Concourse Level) *Imaging Committee (Invitation Only)*

7:00 AM-9:00 AM

Acapulco (Ballroom Level) *Leukemia Working Group (Invitation Only)*

7:30 AM-9:00 AM

San Francisco (Ballroom Level) *Professional Review Committee (Invitation Only)*

7:30 AM-9:30 AM

Haymarket (Concourse Level) *SWOG Data and Safety Monitoring Committee (Invitation Only)*

7:30 AM-9:30 AM

Regency A (Ballroom Level) *Symptom Control and Quality of Life Committee [CME]*

8:00 AM-10:00 AM

Wrigley (Concourse Level) *DEI Committee (Invitation Only)*

8:00 AM-12:00 PM

Crystal C (Lobby Level) *GI Working Group (Invitation Only)*

8:30 AM-9:30 AM

Comiskey (Concourse Level) *Perioperative Physical Activity Study Meeting*

8:30 AM-10:00 AM

Columbian (Concourse Level) *Quality Assurance Committee (Invitation Only)*

8:30 AM-10:30 AM

Crystal A (Lobby Level) *Lymphoma Committee [CME]*

8:30 AM-11:30 AM

Crystal B (Lobby Level) *Nicholas Vogelzang Symposium hosted by the GU Committee*

9:15 AM-10:15 AM

Gold Coast (Concourse Level) *Lung Community Engagement Subcommittee (Invitation Only)*

9:30 AM-11:30 AM

Plaza B (Lobby Level, East Tower) *Breast Working Group (Invitation Only)*

10:00 AM-12:00 PM

Plaza A (Lobby Level, East Tower) *Pharmaceutical Sciences Committee and Drug Information Subcommittee*

10:15 AM-11:45 AM

Regency A (Ballroom Level) *Lung-MAP Update Meeting*

10:30 AM-12:00 PM

Comiskey (Concourse Level) *Bone Marrow & Stem Cell Transplantation Committee [CME]*

11:00 AM-12:00 PM

Regency Foyer (Ballroom Level) *Plenary Reception (Light Hors d'Oeuvres)*

11:30 AM-12:00 PM

Soldier Field (Concourse Level) *Publications Committee (Invitation Only)*

12:00 PM-2:00 PM

Regency B-D (Ballroom Level) *Plenary II (General) [CME]*

2:15 PM-3:15 PM

Crystal C (Lobby Level) *NCORP/MU-NCORP Site PI Meeting*

2:15 PM-4:15 PM

Acapulco (Ballroom Level) *Lung Working Group (Invitation Only)*

Schedule of Events

2:30 PM-4:30 PM

Wrigley (Concourse Level)

Melanoma Working Group
(Invitation Only)

2:30 PM-4:30 PM

Crystal A (Lobby Level)

Barlogie-Salmon Myeloma
Committee [CME]

2:30 PM-6:00 PM

**Plaza Ballroom
(Lobby Level, East Tower)**

GU Working Group (Invitation
Only; Prostate, Renal, Bladder)

3:00 PM-4:00 PM

Water Tower (Concourse Level)

GI Translational Research
Subcommittee (Invitation Only)

3:00 PM-5:00 PM

Comiskey (Concourse Level)

Radiation Oncology Committee
[CME]

3:30 PM-5:30 PM

Soldier Field (Concourse Level)

ORP Executive Committee
(Invitation Only)

3:30 PM-6:30 PM

Regency A (Ballroom Level)

Breast Committee [CME]

4:30 PM-6:30 PM

Regency C (Ballroom Level)

Leukemia Committee [CME]

4:30 PM-6:30 PM

Regency D (Ballroom Level)

GI Committee [CME]

6:00 PM-7:00 PM

Executive Reception (Invitation
Only)

6:45 PM-8:30 PM

Crystal Ballroom (Lobby Level)

Group Reception

SATURDAY, OCTOBER 14, 2023

Group Meeting Registration & Information Desk
6:30 am - 11:00 am: Regency Foyer, Ballroom Level,
West Tower

Hope Foundation Information Desk
8:00 am - 11:00 am: Regency Foyer, Ballroom Level,
West Tower

**Unless otherwise indicated, all meetings are in the
West Tower of the hotel.*

7:00 AM-7:45 AM

Regency B (Ballroom Level)

Board of Governors (Board
Members Only)

8:00 AM-9:00 AM

Regency B (Ballroom Level)

Committee Chairs (Committee
Chairs Only)

9:00 AM-1:00 PM

Acapulco (Ballroom Level)

GI Committee Retreat (Invitation
Only; In Person Only)

9:15 AM-10:15 AM

Comiskey (Concourse Level)

GU Working Group (Invitation
Only; Translational Medicine)

9:15 AM-12:15 PM

Regency C (Ballroom Level)

Lung Committee [CME]

9:30 AM-11:30 AM

Regency B (Ballroom Level)

Melanoma Committee [CME]

9:30 AM-11:30 AM

Water Tower (Concourse Level)

Surgery Committee [CME]

10:15 AM-12:15 PM

Regency A (Ballroom Level)

GU Committee (Open Session)
[CME]



Nicholas J. Vogelzang, MD, GU Symposium

Honoring the many valuable contributions Dr. Vogelzang made in support of his colleagues and patients throughout his career with SWOG Cancer Research Network.

FRIDAY, OCTOBER 13 • 8:30-11:30 AM CT • CRYSTAL B (LOBBY LEVEL, WEST TOWER)

New Approaches to Targeting the Androgen Receptor in Prostate Cancer

8:30-8:40 Welcome and Introduction

8:40-9:05



Intensification of Treatment for Hormone Sensitive Prostate Cancer: Future Directions

Tanya Barauskas Dorff, MD

Advanced Prostate Cancer Chair, SWOG
Section Chief, Genitourinary Disease Program

Professor, Department of Medical Oncology & Therapeutics Research
City of Hope, Duarte, CA

9:10-9:35



Combining AR targeted Therapy and PARP Inhibition in Advanced Prostate Cancer

Neeraj Agarwal, MD, FASCO

Professor of Medicine
Senior Director for Clinical Translation, Huntsman Cancer Institute (HCI)

HCI Presidential Endowed Chair of Cancer Research

Director, Center of Investigational Therapeutics

Director, Genitourinary Oncology Program

Huntsman Cancer Institute, University of Utah (NCI-CCC)

9:40: 10:05



New Ways of Targeting the Androgen Receptor

Daniel P. Petrylak, MD

Professor, Medicine and Urology

Division Chief, Genitourinary Oncology

Smilow Cancer Center at Yale University

10:10-10:35



Bipolar Androgen Therapy in Prostate Cancer: Current Evidence and Future Perspectives

Emmanuel S. Antonarakis, MD

Clark Endowed Professor of Medicine

Associate Director of Translational Research, Masonic Cancer Center

Division of Hematology, Oncology, and Transplantation

University of Minnesota

10:40-11:05



Aggressive Variant Prostate Cancers: The MD Anderson Experience

Paul G. Corn, MD, PhD

Professor, Department of Genitourinary Medical Oncology

Department Chair ad interim, Department of Genitourinary Medical Oncology

The University of Texas MD Anderson Cancer Center, Houston, TX

11:10-11:30

Discussion

The Nicholas J. Vogelzang, MD, Scholarship

Supporting early career investigators with mentorship and travel funding to attend SWOG group meetings

&

The Nicholas J. Vogelzang, MD, GU Symposium

A special group meeting session dedicated to a range of topics in GU research

Give to Support the Vogelzang Fund

thehopefoundation.org/donate

THE HOPE FOUNDATION
FOR CANCER RESEARCH

Committees

Administrative Committees

Board of Governors

Charles D. Blanke, MD

Publications

Hagen F. Kennecke, MD

Conflict Management

Paul Okunieff, MD

Professional Review

Paul Hesketh, MD

Research Support Committees

Adolescent and Young Adult

Rebecca Johnson, MD

Patient Advocates

Rick Bangs, MBA

Bone Marrow and Stem Cell Transplantation

Patrick J. Stiff, MD

Pharmaceutical Sciences

Siu-Fun Wong, PharmD

Digital Engagement

Mark Lewis, MD

Radiation Oncology

Chul Ha, MD

Imaging

Lawrence H. Schwartz, MD

Recruitment and Retention

Allison Caban-Holt, PhD

Oncology Research Professionals

Connie Szczepanek, RN, BSN, CCRP

Surgery

Syed A. Ahmad, MD

Veterans Affairs

Stephen D. Bartlett, RPh

Future Meeting Dates

2024	2025	2026
SPRING April 3-6 Seattle, WA	SPRING April 30-May 3 San Francisco, CA	SPRING April 29-May 2 San Francisco, CA
FALL October 16-19 Chicago, IL	FALL September 17-20 Chicago, IL	FALL October 7-10 Chicago, IL

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

DEI Champion: Manuel Espinoza-Gutarra, MD
 Digital Engagement: TBD
 NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse: Teresa Witcher, BSN, RN
 Patient Advocate: Jack Aiello, MS
 Pharmaceutical Science: Craig Elg, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Sharon Palmer
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Friday, October 13, 2023 2:30 p.m. - 4:30 p.m.

Room: Crystal A (Lobby Level, West Tower)

Agenda

Active Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and P. Hari. Activated: 6/27/19. Temporarily closed to accrual 03/29/23.

S2005, "A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)." Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21. Temporarily Closed: 7/16/21. Re-opened to accrual: 10/15/21. Temporarily closed to accrual 04/08/22.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 05/30/23.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 03/03/23.

EAA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

EAA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

Closed Studies

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Santhorawala. Activated: 3/08/18; Closed: 9/30/19.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/08. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

Barlogie-Salmon Myeloma Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1803	S2005	EAA173	EAA181
Ascension Providence Hospitals - Southfield	1	-	1	-
Banner University Medical Center - Tucson	8	-	-	1
Boston Medical Center	5	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	23	-	3	-
Cancer Research for the Ozarks NCORP	2	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	-	-	-
Cedars-Sinai Medical Center	6	-	-	-
City of Hope Comprehensive Cancer Center	98	-	-	-
Columbus NCI Community Oncology Research Program	8	-	-	-
CommonSpirit Health Research Institute	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	5	-
Froedtert and the Medical College of Wisconsin LAPS	7	-	-	-
Georgia NCI Community Oncology Research Program	13	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-
Heartland Cancer Research NCORP	14	-	-	-
Houston Methodist Hospital	4	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	40	-	-	-
Lahey Hospital and Medical Center	3	-	-	-
Loyola University Medical Center	22	-	3	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	2
Medical University of South Carolina Minority Underserved NCORP	43	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-
Michigan Cancer Research Consortium NCORP	7	-	-	-
Moffitt Cancer Center	41	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	1	-
New Mexico Minority Underserved NCORP	11	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	4	-	-	-
Oregon Health and Science University	25	-	3	8
Pacific Cancer Research Consortium NCORP	15	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-
UC Davis Comprehensive Cancer Center LAPS	20	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	10	-	-	-
University of Arkansas for Medical Sciences	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	30	-	-	-
University of Kentucky/Markey Cancer Center	3	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	13	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-
University of Rochester LAPS	15	-	-	-
University of Texas Health Science Center at San Antonio	14	-	-	-
University of Texas MD Anderson Cancer Center LAPS	24	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	3	1
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	13	-	-	-
Wisconsin NCI Community Oncology Research Program	18	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	3	4
ALLIANCE	181	-	-	-
CCTG	6	-	-	-
ECOG-ACRIN	153	1	-	-
NRG	87	-	-	-
Total	1,036	1	23	20

Barlogie-Salmon Myeloma Committee

CTN 0702, “Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy.” Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, “Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone.” Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).” Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), “High-risk AMM – Revlimid.” Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, “Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone.” Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation

Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).” Drs. S. Kumar, A. Cohen and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

Developing Studies

S2213, “Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis.” Drs. P. Hagen, T. Parker, and S. Sidana.

Proposed Studies- At Triage

Sxxxx, “Phase III Study of Optimal Induction and MRD Driven Maintenance Therapy for Newly Diagnosed High-Risk Multiple Myeloma (HRMM).” Drs. B. Lipe, J.C. Ye, and K. Gowin.

Proposed Studies-Pre-Triage/On Hold

1. **Sxxxx**: “An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma.” Dr. R. Chakraborty.
2. **Sxxxx**: “CAEL-101 in Real AL Amyloidosis”. Dr. D. Bhutani
3. **Sxxxx**: Developing Smoldering Multiple Myeloma Concept. Dr. P. Hagen

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair:Priyanka Sharma, MD
 Executive Officer:..... Anne Chiang, MD, PhD
 Statisticians:Allison Meisner, PhD
 William E. Barlow, PhD
 Danika Lew, MA
 Jieling Miao, MS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology:..... Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging:..... Joanne E. Mortimer, MD
 Wei Tse Yang, MBBS
 Pathology:.....David L. Rimm, MD, PhD
 Early Therapeutics:.....Stephanie L. Graff, MD

Designates

Cancer Control Liaisons: Melinda L. Irwin, PhD, MPH (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
Helen K. Chew, MD (Symptom Control & QOL)
 DEI Champion:.....Gayathri Nagaraj, MD
 Digital Engagement:..... Sarah S. Mougalian, MD
 NCORP Representative:.....Philip E. Lammers, MD
 Veterans Affairs:.....Sarah V. Colonna, MD
 Data Coordinators:.....Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Kevin Moralda, BS
 Larry G. Kaye
 Oncology Research Professionals:
 CRAs:..... Karyn N. Hart, CCRP
 Avidanka Baftirovska, BS, CCRP
 Nurse: Cameo Windham, BSN, RN
 Patient Advocates:..... Roberta A. Albany
 Ginny Mason, RN, BSN
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Protocol Project Manager: Alicia Aranda
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Friday, October 13, 2023 3:30 p.m. - 6:30 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

3:30 - 3:35 pm Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)

Mini symposium: New horizons in Neoadjuvant systemic therapy for breast cancer

3:35-3:50 pm Pathological response and long-term outcomes across breast cancer subtypes - Fraser Symmans MD, Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center

3:50-4:05 pm Neoadjuvant chemo-immunotherapy for Hormone positive breast cancer: Patient selection and trial end points - Erin Cobain MD, Assistant Professor, Department of Internal Medicine Rogel Cancer Center, Michigan

4:05-4:20 pm Neo and adjuvant chemo-immunotherapy for TNBC. Right Sizing the treatment - Zahi Mitri MD, MS, Associate Professor of Medicine, Department of Medicine British Columbia Cancer Agency, Vancouver

4:20 - 4:35 pm Q&A and Panel Discussion

4:35 - 4:45 pm Publication update – William Barlow, PhD

4:45 - 5:00 pm Patient Advocate update – Ginny Mason and Roberta Albany

5:00 - 5:10 pm Translational Medicine Subcommittee update - Alastair Thompson, MD and Andrew K. Godwin, PhD

5:10 - 5:50 pm Review of open CTSU trials

5:50 - 6:10 pm Recently approved and developing Concepts

6:10 - 6:30 pm Reports from Committee Liaisons

Radiotherapy: Reshma Jagsi, MD
 Surgery: Joshua Mammen, MD
 Survivorship: Melinda L. Irwin, PhD, MPH
 Cancer Care Delivery: Dawn Hershman, MD
 Prevention: Banu Arun, MD
 Symptom Control & QOL: Helen K. Chew, MD
 NCORP: Philip Lammers, MD
 DEI: Gayathri Nagaraj, MD

6:30 pm Closing Comments and Adjourn

Breast Committee

Developing Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai.

Active Studies

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 07/21/23.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 09/12/18.

CTSUA011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 01/06/21.

CTSUCCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 05/30/18.

CTSUEA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 02/11/20.

CTSUEA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 04/02/20.

CTSNRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal

to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 06/07/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Pusztai and Mammen. Activated: 11/15/16. Permanently closed: 06/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e³ Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Pusztai. Activated: 09/04/13. Permanently closed: 05/01/19.

CTSUA011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 02/07/14. Permanently closed: 07/01/22.

CTSNRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14. Permanently closed: 05/27/22.

CTSNRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 06/26/15. Permanently closed: 04/22/22.

CTSNRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 03/12/19. Permanently closed: 07/01/22.

CTSNRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 04/13/17. Permanently closed: 12/02/22.

Breast Committee

Active Cancer Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17.

Closed Symptom Control and Quality of Life Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19. Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19. Permanently closed: 11/15/21.

Active Cancer Care Delivery Studies

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordini and Hershman. Activated: 07/16/18.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 07/06/17.

Active Cancer Prevention Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 09/01/20.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 01/13/17. Permanently closed: 03/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15. Permanently closed: 12/30/22.

Breast Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1706	S2007	A011202	A011801	EA1181	EA1183	MA39	NRGBR002
Ascension Providence Hospitals - Southfield	2	-	4	1	5	-	1	-
Banner MD Anderson Cancer Center	-	-	-	3	-	-	-	-
Banner University Medical Center - Tucson	1	-	1	-	10	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved	3	-	1	-	1	-	-	-
Baylor University Medical Center	-	-	1	-	-	-	-	-
Boston Medical Center	-	-	-	5	14	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	3	-	1	-
Cancer Research for the Ozarks NCORP	1	-	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	2	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	4	-	-	-	3	-	-	-
CommonSpirit Health Research Institute	1	-	-	-	-	-	1	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	1	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	-	7	2	-	-
Desert Regional Medical Center	-	-	7	-	2	-	1	-
Essentia Health NCI Community Oncology Research Program	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	-	-	2	-	-	-
Heartland Cancer Research NCORP	3	-	-	1	-	-	-	-
Houston Methodist Hospital	-	-	-	1	-	-	2	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	1	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	6	-	-	-
Loma Linda University Medical Center	-	-	3	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	1	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	-	-	-	3	-	-
Meharry Medical College	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	1	-	-	-	-	-
Montana Cancer Consortium NCORP	3	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	1	-	-	-
New Mexico Minority Underserved NCORP	4	1	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	-	-	-	-
Northwestern University LAPS	1	1	-	-	4	1	-	-

Breast Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1706	S2007	A011202	A011801	EA1181	EA1183	MA39	NRGBR002
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	-	1	-	-	-
Oregon Health and Science University	-	-	-	-	-	3	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Salem Hospital	-	-	4	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	-	1	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	2	5	-	-	-
The Don and Sybil Harrington Cancer Center	3	-	11	2	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	2	-	-	-	-	-
The West Clinic - Wolf River	-	-	9	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	6	-	2	-	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	3	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	4	1	-	-	2	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	2	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	42	1	11	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	4	-	-	-	1	-
University of Michigan Comprehensive Cancer Center LAPS	2	-	-	1	1	-	7	-
University of Mississippi Medical Center	-	-	-	-	1	-	-	-
University of Rochester LAPS	1	-	-	-	1	-	-	-
University of Texas Health Science Center at San Antonio	-	1	6	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	1	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	4	-	-	1	7	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	11	2	14	4	1	-
William Beaumont Hospital-Royal Oak	-	-	6	-	-	-	-	1
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	3	10	-	-	-
ALLIANCE	16	6	-	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-
ECOG-ACRIN	6	2	-	-	-	-	-	-
NRG	42	-	-	-	-	-	-	-
Total	131	20	129	29	114	13	18	1

Breast Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGBR003	NRGBR004	NRGBR005	NRGBR007
Ascension Providence Hospitals - Southfield	3	1	-	-
Banner MD Anderson Cancer Center	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved	-	1	-	-
Baylor University Medical Center	-	-	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	9	1	-	-
Cancer Research for the Ozarks NCORP	3	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-
Desert Regional Medical Center	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Georgia NCI Community Oncology Research Program	1	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Houston Methodist Hospital	-	-	1	-
Kaiser Permanente NCI Community Oncology Research Program	25	1	-	-
Lahey Hospital and Medical Center	-	1	-	-
Loma Linda University Medical Center	-	-	-	-
Loyola University Medical Center	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-
Meharry Medical College	1	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwell Health NCORP	-	-	-	2
Northwestern University LAPS	1	-	-	-

Breast Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGBR003	NRGBR004	NRGBR005	NRGBR007
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	3	-	-	-
Pacific Cancer Research Consortium NCORP	2	-	-	-
Salem Hospital	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Sutter Cancer Research Consortium	4	2	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-
The West Clinic - Wolf River	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-	-
UC San Diego Moores Cancer Center	1	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	1	-
University of Michigan Comprehensive Cancer Center LAPS	3	-	-	-
University of Mississippi Medical Center	-	-	-	-
University of Rochester LAPS	9	-	-	1
University of Texas Health Science Center at San Antonio	4	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	3	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	6	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	9	1	-	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	90	9	7	4

Cancer Control & Prevention Committee

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Cmte Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Cancer Survivorship Cmte Co-Chairs: Halle C.F. Moore, MD
 Melinda L. Irwin, PhD, MPH
 Palliative & End of Life Cmte Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention and Epidemiology Cmte Co-Chairs: Banu Arun, MD
 Marian L. Neuhouser, PhD, RD
 Symptom Control & QOL Cmte Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (CCD, Prevention,
 Symptom Control & QOL)
 Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Garnet Anderson, PhD
 Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Riha Vaidya, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Phyllis J. Goodman, MS
 Danika Lew, MA
 Anna Moseley, MS
 Sarah Colby, MS
 Administrative Lead
 Statistics & Data Management Center (SDMC): Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Mark A. O'Rourke, MD
 Radiation Oncology Committee: Eileen P. Connolly, MD, PhD (CCD,
 Prevention)
 Kiri A. Cook, MD (Survivorship, Symptom Control & QOL)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James (Jimmy) Rae, PhD

Liaisons:

Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Melinda L. Irwin, PhD, MPH (Survivorship)
 Helen K. Chew, MD (Symptom Control & QOL)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD

Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Genitourinary Committee: Peter J. Van Veldhuizen, Jr., MD
 International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: Hayder Saeed, MD
 Melanoma Committee: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Recruitment and Retention Committee: Allison M. Caban-Holt, PhD
 Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
 Krishna Soujanya Gunturu, MD (Survivorship)
 Mina S. Sedrak, MD (CCD)
 Katherine D. Crew, MD (Prevention)
 Michael J. Fisch, MD (Symptom Control & QOL)
 Veterans Affairs: Yeun-Hee Anna Park, MD

Designates

Oncology Research Professionals

Clinical Research Associates: Amanda R. Dinsdale, MHA, CCRP
 Amy Jo Koffarnus, BS, CCRP
 Samantha Wright, MS, CCRP
 Shirley S. Sui, BS
 Nurses: Connie Szczepanek, RN, BSN
 Melyssa W. Foust, MSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Siu-Fun Wong, PharmD
 Sun "Coco" Yang, PharmD, PhD
 SDMC Data Coordinators and Staff: Kimberly Carvalho, BA
 Sam Dzingle, BA
 Matthew Eng, PharmD
 Manny Kharbanda, BS
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment and Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Amy Geschwender, PhD (Symptom Control & QOL)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Cheryl L. Jernigan, CPA (Prevention & Epidemiology)
 Valerie Fraser (Palliative & End of Life Care)
 Protocol Project Manager (Cancer Care Delivery;
 Prevention and Epidemiology): Patricia O'Kane
 Protocol Project Manager (Survivorship): Megan Keim

Cancer Control & Prevention Committee

Protocol Project Manager (Symptom Control and
Quality of Life):..... Justine Trevino
Protocol Project Manager (Palliative Care): Andrea Garcia
Clinical Trials Program Manager (Palliative Care;
Symptom Control):.....Laura Gildner, MS
Clinical Trials Program Manager (CCD; Prevention;
Survivorship): Mariah Norman, MS

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD

Time/Location

Thursday, October 12, 2023 8:00 a.m. - 10:00 a.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

Presentations

Harnessing Implementation Science and Digital Health to Promote Evidence-based Management of Cancer-related Fatigue, Erin Gillespie, MD, University of Washington, Fred Hutchinson Cancer Center

Disparities in Access to Novel Hormonal Therapies in Prostate Cancer, Hiba Khan, MD, MPH, Fred Hutchinson Cancer Center

Improving Health Insurance Literacy, Financial Toxicity, and Follow-up Care Among Young Adult Cancer Survivors, Anne Kirchhoff, PhD, MPH, University of Utah, Huntsman Cancer Institute

Lay Health Worker-led Intervention to Promote Goals of Care Communication, Manali Patel, MD, MPH, MS, Stanford University; Ravi Parikh, MD, University of Pennsylvania; Christopher Manz, MD, Dana Farber Cancer Institute

Active Studies

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Veena Shankaran, MD, University of Washington. Activated 7/26/21.

S2108CD, "Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care." Dr. Jens Rueter, MD, Maine Cancer Genomics Initiative; Dr. Meghna Trivedi, MD, Columbia University

S1703, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer," Dr. Melissa Accordini, MD, Activated 7/16/18.

Developing Studies/Miscellaneous Updates

S2309CD, "Preventing Financial Adversity Among Early-stage Cancer Patients through Unrestricted Cash (PAYMENT)." – Dr. Veena Shankaran,

MD, University of Washington

- Will resubmit in fall 2023.

A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. Christine Veenstra, MD, University of Michigan

- Discussed with the NCI on 8/16/23, planning to submit a R01 in fall 2023.

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, MD, MBA, Izumi Okado, PhD, University of Hawaii

Closed Studies

S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

S1204, Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation, Dr. R. Vaidya

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger

Published Studies

Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials. Dr. J. Unger

Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-related Cancers, 1986 to 2016. Dr. R. Vaidya

Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231601C	A231901C	ACCL16N1	EAQ171CD
Ascension Providence Hospitals - Southfield	-	-	-	4	-	-	-	-
Banner University Medical Center - Tucson	1	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	1	-	-
CWRU Case Comprehensive Cancer Center LAPS	21	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	4	-	-	-	-	3	-
Cancer Research for the Ozarks NCORP	-	7	14	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	11	4	18	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	8	1	66	-	-	-	-	-
Columbia University Minority Underserved NCORP	21	7	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	10	-	18	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	3	1	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	40	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	15	-	-	-	17	-
Gulf South Minority Underserved NCORP	6	-	-	-	2	-	-	-
Hawaii Minority Underserved NCORP	8	2	41	-	-	-	-	-
Heartland Cancer Research NCORP	17	5	58	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	4	6	-	-	-	-	34	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-
Kansas Institute of Medicine Cancer and Blood Center	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	-	5	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	10	9	17	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-

Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231601C	A231901C	ACCL16N1	EAQ171CD
Montana Cancer Consortium NCORP	9	-	34	-	-	-	-	-
Mount Sinai Hospital	2	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	-	22	-	-	-	1
NCORP of the Carolinas (Prisma Health NCORP)	6	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	2	1	-	1	-	-	-	-
New Mexico Minority Underserved NCORP	15	2	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	10	6	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	5	1	2	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	3	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	4	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	1	46	-	-	-	-	-
University of Rochester LAPS	4	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	2	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	2	20	-	-	-	-	-
Western States Cancer Research NCORP	-	1	-	1	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	3	4	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	35	-	-	-	-	-	-	-
ALLIANCE	13	7	27	-	-	-	-	-
ECOG-ACRIN	22	10	7	-	-	-	-	-
NRG	18	2	-	-	-	-	-	-
Total	290	86	423	39	2	1	54	6

Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	<i>NHLBIMDS NRGCC007</i>	
<i>Ascension Providence Hospitals - Southfield</i>	1	-
<i>Banner University Medical Center - Tucson</i>	-	-
<i>Baptist Memorial Health Care/Mid South Minority Underserved NCORP</i>	3	-
<i>CWRU Case Comprehensive Cancer Center LAPS</i>	5	-
<i>Cancer Research Consortium of West Michigan NCORP</i>	-	-
<i>Cancer Research for the Ozarks NCORP</i>	-	-
<i>Cancer Research of Wisconsin and Northern Michigan Consortium</i>	-	-
<i>Carle Cancer Center NCI Community Oncology Research Program</i>	1	-
<i>Columbia University Minority Underserved NCORP</i>	20	-
<i>Columbus NCI Community Oncology Research Program</i>	-	-
<i>CommonSpirit Health Research Institute</i>	-	-
<i>Cotton O'Neil Cancer Center / Stormont Vail Health</i>	-	-
<i>Dayton NCI Community Oncology Research Program</i>	-	-
<i>Essentia Health NCI Community Oncology Research Program</i>	-	-
<i>Fred Hutchinson Cancer Research Center LAPS</i>	20	-
<i>Georgia NCI Community Oncology Research Program</i>	-	-
<i>Gulf South Minority Underserved NCORP</i>	-	-
<i>Hawaii Minority Underserved NCORP</i>	5	-
<i>Heartland Cancer Research NCORP</i>	-	1
<i>Kaiser Permanente NCI Community Oncology Research Program</i>	7	-
<i>Kansas City Veterans Affairs Medical Center</i>	4	-
<i>Kansas Institute of Medicine Cancer and Blood Center</i>	2	-
<i>Lahey Hospital and Medical Center</i>	-	-
<i>Loyola University Medical Center</i>	-	-
<i>Massachusetts Veterans Epidemiology Research and Information Center</i>	32	-
<i>Medical University of South Carolina Minority Underserved NCORP</i>	4	-
<i>Michigan Cancer Research Consortium NCORP</i>	-	-
<i>Moffitt Cancer Center</i>	8	-

Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	NHLBIMDS	NRGCC007
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	-
MultiCare Tacoma General Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
Nevada Cancer Research Foundation NCORP	-	-
New Mexico Minority Underserved NCORP	-	-
Northwell Health NCORP	14	-
Oregon Health and Science University	11	-
Pacific Cancer Research Consortium NCORP	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	23	-
UC San Diego Moores Cancer Center	31	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	9	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	22
University of Rochester LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-
Western States Cancer Research NCORP	-	-
William Beaumont Hospital-Royal Oak	2	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	7	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	211	23

Cancer Survivorship Committee

Leadership

Co-Chairs: Melinda Irwin, PhD, MPH
 Halle Moore, MD

Time/Location

Thursday, October 12, 2023 5:15 p.m. - 7:15 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

Welcome: Melinda Irwin and Halle Moore

Survivorship Presentation:

Invited speaker: Frank Penedo, PhD, Professor and Associate Director,
 Cancer Survivorship and Behavioral Translational Sciences, Director of
 Cancer Survivorship Program and Co-Leader of Cancer Control Research
 Program, Sylvester Comprehensive Cancer Center at University of Miami

Discussion

Patient Advocate Update: Lee Jones

New Ideas:

Laura Graham: Randomized phase II trial of vortioxetine for the reduction
 of ADT-induced cognitive impairment.

Suzie Zick and Heather Greenlee: Testing the Fatigue Diet in People with
 Early-Stage Breast Cancer: The BETTER Study (Breast diET faTigue canCER)

Rina Fox and Terry Badger: App-supported sleep coaching among cancer
 survivors and their bedroom partners

Ash Albert: Cohort study to understand and improve experiences and
 outcomes of transgender people diagnosed with cancer

John Krauss: GLP-1 agonist for cancer patients in survivorship with a BMI
 greater than 30

Updates:

Justin Floyd and Monika Leja: [S1501](#), "Prospective Evaluation of Carvedilol
 in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+
 Breast Cancer."

Dan Raz and Virginia Sun: [S2204](#), "Randomized Phase III Trial of a
 Perioperative Physical Activity Intervention in Older Adults with Lung
 Cancer and their Family Caregivers." (City of Hope/SWOG hybrid)

Krishna Gunturu: [S2013](#) I-CHECKIT: Immune CHECKpoint Inhibitory Toxicity
 analysis: (Also in QOL and Symptom Control Committee)

Vickie Baracos: [SWOG 0816](#) a secondary analysis of predictors of muscle
 wasting

Erin Roesch: Update on breast committee SAGE study

Use of Continuous Glucose Monitoring to Improve Glycemic Safety and
 Reduce Infectious Complications in AYA ALL patients: GOG led (Allison
 Grimes), SWOG champion is Stephanie Tsai

ALTE2131: "Gonadotropin-Releasing Hormone Analogs (GnRHa) and
 Protection of Ovarian Reserve in Adolescents and Young Adults with
 Cancer." COG led, SWOG champion is Halle Moore

Liaison Updates/Other Business

Active Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac
 Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. J.
 Floyd and M. Leja. Activated 9/15/2017.

Closed Study

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel
 Obstruction." Drs. R. Krouse, J. Denevee, and V. Sun. Activated: 3/9/15;
 Permanently Closed: 5/15/20.

Cancer Survivorship Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1501
Ascension Providence Hospitals - Southfield	4
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	6
Bay Area Tumor Institute NCORP	2
CWRU Case Comprehensive Cancer Center LAPS	14
Cancer Research for the Ozarks NCORP	10
City of Hope Comprehensive Cancer Center	47
Columbia University Minority Underserved NCORP	2
CommonSpirit Health Research Institute	1
Fred Hutchinson Cancer Research Center LAPS	4
Georgia NCI Community Oncology Research Program	12
Gulf South Minority Underserved NCORP	4
Heartland Cancer Research NCORP	20
Henry Ford Hospital	2
Kaiser Permanente NCI Community Oncology Research Program	1
King Faisal Specialist Hospital and Research Centre	3
Lahey Hospital and Medical Center	6
Loyola University Medical Center	8
Medical University of South Carolina Minority Underserved NCORP	1
Michigan Cancer Research Consortium NCORP	3
Moffitt Cancer Center	23
Montana Cancer Consortium NCORP	1
NCORP of the Carolinas (Prisma Health NCORP)	2
National Cancer Center-Korea	1
New Mexico Minority Underserved NCORP	6
Oregon Health and Science University	1
UC Davis Comprehensive Cancer Center LAPS	2
USC Norris Comprehensive Cancer Center LAPS	4
University of Kansas Cancer Center - MCA Rural MU NCORP	7
University of Michigan Comprehensive Cancer Center LAPS	10
Wayne State University - Karmanos Cancer Institute LAPS	6
ALLIANCE	22
ECOG-ACRIN	40
NRG	22
Total	297

Palliative and End of Life Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Marie Bakitas, DNSc, CRNP

Time/Location

Thursday, October 12, 2023 10:15 a.m. - 12:15 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

Welcome and Introductions: Co-Chairs

5 mins: Committee Liaison Updates - Patient Advocates/ORP

20 mins: Plenary: S1820, "A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)." Dr. Sun. Activated: 12/9/19. Permanently Closed to Accrual for Step 1: 4/12/22

30 mins:

(Triage Approved) Developing Studies Updates

S2408, "Randomized multicenter placebo-controlled trial evaluating lanreotide for the reduction of postoperative pancreatic fistulae." Jonathan G. Sham, MD, Charles A. Coltman, Jr. Fellow

(Pre-Triage) Developing Studies Updates

Depression Screening and Treatment in Patients Requesting Medical Aid in Dying (MAID)" (U34-June submission) – Drs. Blanke and Fairman

Optimizing Distress Screening and Support of Family Caregivers of Persons with Advanced Cancer (FamilyStrong) using a SMART Design PI– J. Nicholas Dionne-Odom, PhD, RN

Phase III Trial of Telehealth Intervention for Self-Management of Eating after Gastroesophageal Cancer Surgery – Jae Kim, MD and Virginia Sun, PhD, RN

PIPAC in Refractory Colorectal/ Appendiceal Carcinomatosis – Mustafa Raouf, MD, MS, Robert S. Krouse, MD

Secondary analysis

Depression in SWOG Advanced Cancer Trials: Incidence and Importance. Drs. Nehemiah, Blanke, Fairman, and Krouse

5 mins: Closed Study Update

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15; Closed: 5/15/20.

10 mins: New Concepts

Dr. Jaclyn Wall and her application to the Hope Foundation's Dr. Charles A. Coltman, Jr., Fellowship Program for her project "Improving Palliative and Supportive Care Utilization in Women with Gynecologic Cancers." --UAB

45 mins: Pre-SWOG Pilot Study Updates

"Study of Breast Cancer Survivor Symptoms Correlation with Fatigue Measured by Prolonged Wrist Actigraphy," Lauren A. Fowler PhD and Jamie S. Myers PhD, RN

Sleep Hygiene Education, ReadWatch™ actigraphy, and telehealth cognitive behavioral training for insomnia Effect on Symptom Relief for Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) (SHERE-Relief 2), funded by the Oncology Nursing Foundation as an RE03 two-year grant. Jamie S. Myers, PhD, RN and Lauren A. Fowler, PhD

Feasibility Study of a Hope Workshop Intervention Designed to Improve Cancer Survivor Hopefulness and Endocrine Therapy Adherence," David Feldman, PhD and Ben Corn, MD

Feasibility and Acceptability of an Online Intervention to Enhance Hopefulness Among Oncology Professionals. David Feldman, PhD and Ben Corn, MD

5 mins: Closing Comments and Adjourn: Co-Chairs

Palliative and End of Life Care Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1820
Banner University Medical Center - Tucson	1
City of Hope Comprehensive Cancer Center	3
Columbus NCI Community Oncology Research Program	1
Fred Hutchinson Cancer Research Center LAPS	6
Hawaii Minority Underserved NCORP	2
Heartland Cancer Research NCORP	7
Michigan Cancer Research Consortium NCORP	2
NCORP of the Carolinas (Prisma Health NCORP)	5
New Mexico Minority Underserved NCORP	2
Northwestern University LAPS	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	10
University of Cincinnati Cancer Center-UC Medical Center	1
University of Texas MD Anderson Cancer Center LAPS	11
Upstate Carolina Consortium Community Oncology Research Program	3
Virginia Mason Medical Center	5
ALLIANCE	4
ECOG-ACRIN	1
NRG	29
Total	95

Prevention & Epidemiology Committee

Leadership

Co-Chairs: Banu Arun, MD
 Marian L. Neuhouser, PhD, RD

Time/Location

Thursday, October 12, 2023 12:30 p.m. - 2:30 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

Introduction

Welcome and Opening Comments: Marian Neuhouser and Banu Arun

Cancer Prevention Keynote Presentation

"Commonly used medication and its role in gynecologic cancer prevention" Dr. Britton Trabert, Associate Professor, University of Utah School of Medicine, Huntsman Cancer Institute

Patient Advocate update: Cheryl Jernigan

Active Studies

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.

Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

Other Group Studies with SWOG Study Champions

CTSU A151804, "Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated: 1/31/20.

CTSU A212102, "A Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. B. Arun. SWOG Activated: 7/6/17.

CTSU/NHLBI-MDS, "The National Myelodysplastic Syndromes Natural History Study." Drs. D. Hill and C. Arana Yi. Activated: 4/5/16.

Concept Reviewed by Cancer Prevention Steering Committee

S2311, Treatment Persistence with Alternate Doses of Exemestane or Tamoxifen among Postmenopausal Women with Atypical Hyperplasia, Lobular Carcinoma in situ or Hormone Receptor-Positive Ductal Carcinoma in situ. Dr. J. McGuinness.

Studies approved by triage to be submitted for federal funding

S2405, Pilot Study of Intraoperative Radiotherapy (IORT) versus Observation for Postmenopausal Women with Low-Risk Ductal Carcinoma In Situ (DCIS) after Breast Conserving Surgery." Dr. E. Connolly. Expected to be submitted as U34 in October 2023.

Potential amendments to existing or completed studies

Amendment to S1007, "Effects of Chemoprevention and Adjuvant Endocrine Therapy on a Convolutional Neural Network-Based Breast Cancer Risk Model Using Mammographic Datasets from S0812 and S1007." Drs. K. Crew, K. Kalinsky, R. Ha.

Amendment to S1904, "Application of a Convolutional Neural Network-Based Mammographic Evaluation to Refine Breast Cancer Risk Prediction and Assess Response to Breast Cancer Chemoprevention."

New Business/Open Discussion for new ideas

Prevention & Epidemiology Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC008
Ascension Providence Hospitals - Southfield	1	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	12	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	15	-	-	-	-
Banner MD Anderson Cancer Center	10	3	-	-	-	57	-	-	-
Banner University Medical Center - Tucson	-	11	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved	4	-	3	-	-	2	-	-	-
Bay Area Tumor Institute NCORP	1	6	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	2	-	4
Brooke Army Medical Center	1	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	191	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	3	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	4	18	-	-	2	-	-	-
City of Hope Comprehensive Cancer Center	1	-	16	2	-	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	29	1	-	-	-	-	-
Columbus NCI Community Oncology Research Program	6	8	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	4	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	5	-	-	-	100	-	-	-
Georgia Cares Minority Underserved NCORP	2	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	13	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	10	3	16	-	-	28	-	-	-
Heartland Cancer Research NCORP	2	14	8	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	4	133	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	40	138	10	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	3	-	-	-	-	-	-
Loma Linda University Medical Center	2	6	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	3	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Cntr	3	-	-	-	5	-	8	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	4	-	-	-
Meharry Medical College	1	-	-	-	-	-	-	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	-	8	-	-	-
Mercy Medical Center - Des Moines	1	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	12	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-	-	-	-	-

Prevention & Epidemiology Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC008
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	460	-	-	-
Nevada Cancer Research Foundation NCORP	1	1	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	2	10	-	-	-	-	-	-	-
Northwell Health NCORP	2	11	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	7	-	-	-	-	-	-	-
Oregon Health and Science University	-	15	-	-	-	-	1	1	-
Pacific Cancer Research Consortium NCORP	2	-	-	-	-	-	-	-	-
Salem Hospital	-	3	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	2	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	33	3	-	-	5	-	-	-	-
UC San Diego Moores Cancer Center	-	21	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	30	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	31	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	376	2	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	5	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	20	-	-	2	2	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	9	-	-	-
University of Mississippi Medical Center	1	6	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	7	-	-	-	-	-	-	-
University of Rochester LAPS	-	15	-	-	-	261	-	-	-
University of Texas Health Science Center at San Antonio	9	-	-	-	14	-	-	-	1
University of Texas MD Anderson Cancer Center LAPS	5	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	21	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	619	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	6	-	-	-	-	-	-	-
Virginia Mason Medical Center	11	14	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	2	-	-	-	-	2	-	-	-
Western States Cancer Research NCORP	1	-	-	-	-	69	-	-	-
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	25	-	-	-	-	-	-	-	-
ALLIANCE	37	80	82	-	-	-	-	-	-
CCTG	-	148	-	-	-	-	-	-	-
ECOG-ACRIN	34	64	26	-	-	-	-	-	-
NRG	38	45	59	-	-	-	-	-	-
Total	354	776	294	3	45	2,323	13	1	6

Symptom Control & Quality of Life Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Friday, October 13, 2023 7:30 a.m. - 9:30 a.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

Presentations

Evaluation and Measurement of Cognitive Function in Patients with Cancer:
 Lessons Learned from Cooperative Group Trials
 Plenary speaker: Jeffrey Wefel, PhD, ABPP

SWOG PRO Core: The Essential Core that Supports PRO Development in
 SWOG Treatment Trials
 Speaker: Riha Vaidya, PhD

Active Trials

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating
 The Effect Of Immune-Enhancing Nutrition On Radical Cystectomy
 Outcomes"- Dr. Hamilton-Reeves.

S2013, "Immune Checkpoint Inhibitor Toxicity (I-Checkit): A Prospective
 Observational Study" – Dr. Gunturu

S2205, "STOP CIPN: Randomized trial of Limb Cryocompression versus
 Continuous Compression versus Low Cyclic Compression for the
 Prevention of Taxane-Induced peripheral Neuropathy." Dr. Accordino

S2010, "Improving Endocrine Therapy Persistence in Young Women with
 Breast Cancer using Active Symptom Monitoring." Dr. Henry

Other Concepts in Development

Acupuncture to decrease symptom burden in patients with metastatic
 breast cancer. Dr. Greenlee

Emerging from the Haze™ (Haze)- A multi-dimensional, psycho-educational,
 cognitive rehabilitation program to improve perceived cognitive
 function for cancer survivors. Dr. Myers

Closed Trials

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in
 Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving
 Anti-Cancer Therapy for Solid Tumors." Dr. Hwang, Activated 2/21/19,
 reactivated 7/1/21, Closed 11/15/2022

S1714, "A Prospective Observational Cohort Study To Develop A Predictive
 Model Of Taxane-Induced Peripheral Neuropathy In Cancer Patients"- Dr.
 Trivedi, Activated 3/1/19. Closed 11/15/2021

S0702, "A Prospective Observational Multicenter Cohort Study to Assess
 the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with
 Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak,
 Activated 12/15/2008. Closed 12/13/2013.

S1200, "Randomized Blinded Sham- and Waitlist-Controlled Trial of
 Acupuncture for Joint Symptoms Related to Aromatase Inhibitors
 in Women with Early Stage Breast Cancer." Dr. Hershman. Activated:
 3/27/2012. Closed: 2/15/2017

Committee Business

1. What is happening with our open studies?
2. What other studies are we planning?
3. What other updates should we know about
 - Patient Advocate update
 - Statistical Center update

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of
 Olaparib Administered Concurrently with Radiotherapy for Inflammatory
 Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival
 of Patients Monitored with Serum Tumor Marker Directed Disease
 Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic
 Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs.
 Accordino, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial
 Hardship Through Delivery of a Proactive Financial Navigation
 Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated:
 7/26/21.

S2108CD, "A Cluster Randomized Trial Comparing an Educationally
 Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice
 to Increase Evidence-Based Genome-Informed Therapy." Drs. Reuter,
 Trivedi, Symington, et al. Activated: 8/22/22.

Symptom Control & Quality of Life Committee

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

Lymphoma

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Myeloma

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

Prevention and Epidemiology

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

NCTN Studies

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Control & Quality of Life Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1600	S1614	S2010	S2013	S2205	A221702	A221805	A222004	EAQ202	EAZ171	NRGCC010
Ascension Providence Hospitals - Southfield	-	-	-	23	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	7	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	1	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	1	-	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	1	2	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	1	-	-	-	-	-	-	-
Cancer Res of Wisconsin and N Michigan Consortium	-	-	-	67	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	8	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	22	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	27	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	3	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	10	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	12	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	54	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	4	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	1	20	-	-	-	-	-	1	3
Heartland Cancer Research NCORP	-	-	6	163	-	-	-	-	-	-	-
Henry Ford Hospital	8	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	2	4	38	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	1	46	-	-	-	-	-	-	-
MAVERIC	-	-	-	31	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved	-	-	-	-	-	-	-	-	-	2	-
Mercy Medical Center - Des Moines	-	-	-	9	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	2	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	39	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	4	-	-
Oregon Health and Science University	-	-	-	12	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	2	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	1	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	19	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	89	1	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	5	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	73	-	-	7	-	-	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	5	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	18	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	11	-	-	15	-	1	2	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	49	-	1	41	-	-	2	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	6	-	-	-	-	-	-	-	-
University of Rochester LAPS	15	-	-	-	-	14	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	29	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	1	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	2	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	17	-	-	-	-	-	-	-
ALLIANCE	5	-	2	189	2	-	-	-	-	-	-
ECOG-ACRIN	4	-	-	72	-	-	-	-	-	-	-
NRG	2	1	3	132	-	-	-	-	-	-	-
Total	185	4	29	1,187	3	17	8	2	43	3	3

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Megan Othus, PhD
 Anna B. Moseley, MS

Designates

Data Coordinator: Christine Magner
 Digital Engagement: Kanwal Raghav, MD, MBBS
 Oncology Research Professionals:
 CRAs: TBD
 Nurse: TBD
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: Marcia K. Horn, JD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Early Therapeutics Liaisons

Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD
 Genitourinary Committee Liaison: Neeraj Agarwal, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgeel, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: Jeffrey A. Sosman, MD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Time/Location

Thursday, October 12, 2023 10:00 a.m. - 12:15 p.m.
 Room: Regency D (Ballroom Level, West Tower)

Agenda

10:00 - 10:05 am Welcome and Introduction - Razelle Kurzrock, MD
 10:05 - 10:25 am Updates from Sarcoma Working Group - Lara Davis, MD
 10:25 - 10:45 am S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas" - David Zhen, MD
 10:45 - 11:10 am CIMAC and Translational Immunology in DART - Young Kwang Chae, MD

11:10 - 11:30 am Translational Findings from Non-Pancreatic Neuroendocrine DART Cohorts from CIMAC - Cara Haymaker, PhD
 11:30 - 11:50 am Update from CNS Working Group - Manmeet Ahluwalia, MD
 11:50 - 12:10 pm ComboMATCH - speaker TBD
 12:10 - 12:15 pm Wrap Up - Razelle Kurzrock, MD

Active Studies

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20.

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18.

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/03/2022.

CTSU/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma". SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion: Dr. D'Souza. Activated: 5/8/17.

Early Therapeutics & Rare Cancers Committee

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thoroscopic Management of Pulmonary Metastases in Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma" SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20

Studies in Development

S2310, "Phase II Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk, Resectable Sarcoma". Dr. Harris

Closed Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NCICOV19, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Ceirbhail. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/2021

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigette B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015. Closed: 12/23/2022

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/2023.

Proposed Studies

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG-BN1855, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Temozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

NRG-HN1854, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

NRG-UC1805, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

ComboMatch

Active Studies

EAY191-S3, "Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors." Study Chairs: Reva Basho, M.D., Haider Mahdi, M.

Early Therapeutics & Rare Cancers Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1609	S2012	A071401	AGCT1531	EAY131
Ascension Providence Hospitals - Southfield	1	-	-	-	3
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	2	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	3
CWRU Case Comprehensive Cancer Center LAPS	7	-	-	-	10
Cancer Research for the Ozarks NCORP	1	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	3	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	3	-	-	-	-
Cedars-Sinai Medical Center	8	-	-	-	6
City of Hope Comprehensive Cancer Center	2	-	-	-	6
Columbus NCI Community Oncology Research Program	3	-	-	-	-
CommonSpirit Health Research Institute	15	-	1	-	9
Dayton NCI Community Oncology Research Program	2	-	-	-	1
Essentia Health NCI Community Oncology Research Program	4	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	10	2	-	-	2
Georgia NCI Community Oncology Research Program	6	-	-	-	-
Gulf South Minority Underserved NCORP	2	-	-	-	-
Hawaii Minority Underserved NCORP	4	-	-	-	1
Heartland Cancer Research NCORP	15	-	-	-	1
Henry Ford Hospital	17	-	-	-	11
Houston Methodist Hospital	-	-	-	-	1
Intermountain Medical Center	1	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	27	-	-	-	6
Loma Linda University Medical Center	6	-	-	-	1
Loyola University Medical Center	4	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	6	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	4	-	-	-	2
Mercy Medical Center - Des Moines	2	-	-	-	-
Michigan Cancer Research Consortium NCORP	12	2	-	-	-
Mission Hospital	-	-	-	-	3
Moffitt Cancer Center	22	-	-	-	-
Montana Cancer Consortium NCORP	16	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-
Nevada Cancer Research Foundation NCORP	18	-	-	-	-

Early Therapeutics & Rare Cancers Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1609	S2012	A071401	AGCT1531	EAY131
New Mexico Minority Underserved NCORP	18	-	-	-	-
Northwestern University LAPS	16	-	1	-	-
Oregon Health and Science University	12	-	-	-	-
Pacific Cancer Research Consortium NCORP	12	-	-	-	-
Saint Luke's Hospital of Kansas City	-	-	-	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	1	-	-	5
Sutter Cancer Research Consortium	2	-	-	-	4
The Don and Sybil Harrington Cancer Center	-	-	-	1	-
Tulane University Health Sciences Center	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	11	-	-	-	9
UC Irvine Health/Chao Family Comprehensive Cancer Center	8	-	1	-	19
UC San Diego Moores Cancer Center	27	-	2	-	-
USC Norris Comprehensive Cancer Center LAPS	4	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	3
University of Colorado Cancer Center LAPS	6	-	1	-	9
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	-	6
University of Kentucky/Markey Cancer Center	-	-	-	-	13
University of Michigan Comprehensive Cancer Center LAPS	32	-	-	-	24
University of Mississippi Medical Center	5	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	-	-	-
University of Rochester LAPS	5	-	-	-	-
University of Texas Health Science Center at San Antonio	5	-	-	-	7
University of Texas MD Anderson Cancer Center LAPS	19	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	3	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	1	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	3
Wisconsin NCI Community Oncology Research Program	12	-	-	-	-
Yale University - Yale Cancer Center LAPS	7	-	2	-	13
ALLIANCE	106	6	-	-	-
ECOG-ACRIN	78	-	-	-	-
NRG	138	3	-	-	-
Total	798	15	8	1	183

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena G. Chiorean, MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakhri, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Jonathan R. Strosberg, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Maheswari Senthil, MD

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 Mark A. O'Rourke, MD (Palliative Care)
 DEI Champion: Colmar Figueroa-Moseley, PhD, MPH
 Rachael Ann Safyan, MD
 Digital Engagement: Heloisa Soares, MD, PhD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner
 Oncology Research Professionals:
 CRA: Michelle A. Springer, BA
 Nurse: TBD

Patient Advocate (Pancreatic): Carole Seigel, MBA
 Patient Advocate (Colon): Florence Kurttila, MS
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, October 13, 2023 4:30 p.m. - 6:30 p.m.
 Room: Regency D (Ballroom Level, West Tower)

Agenda

1. Welcome
2. Announcements & Introductions

	Philip Philip
	E. Gabriella Chiorean
3. DEI Subcommittee Initiatives

	Rachel Safyan, Colmar
	Figueroa-Moseley, Carole Seigel, Florence Kurttila
4. SWOG GI Committee Led Trials

	a. S1922	Michael Overman
	b. S2001	Vincent Chung
	c. S2104	Heloisa Soares/Syed Ahmad
	d. S2107	Van Morris
	e. S0802	Jason Zell
	f. S2012	David Zhen
	g. S2303	Anwaar Saeed/Paul Oberstein
5. Correlative Science Updates

	a. S1505	Davendra Sohal/Andy Lowy
--	----------	--------------------------
6. Anal and Rectal

	Hagen Kennecke, Lisa Kachnic	
	a. Major recent clinical results	
	b. NCTN trials update	
	c. Future SWOG plans	
7. Colon

	Marwan Fakhri, Philip Gold, Sepideh Gholami	
	a. Major recent clinical results	
	b. NCTN trials update	
	c. Future SWOG plans	
8. Gastroesophageal

	Syma Iqbal, Zev Wainberg	
	a. Major recent clinical results	
	b. NCTN trials update	
	c. Future SWOG plans	

Gastrointestinal Committee

9. Hepatobiliary

Anthony El-Khoueiry,
Rachna Shroff

FOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma" Dr. Sohal, Dr. Pillarisetty

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

Active Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

CTSU/A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Dr. Zhen. Activated: 6/18/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

10. Neuroendocrine

Jon Strosberg, Arvind Dasari

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas." Activated Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/02/2021

CTSU/A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18. Temporarily Closed to Accrual as of 08/07/2023

11. Pancreatic

Davendra Sohal, Andrew Lowy

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

Hepatobiliary

Active Studies

12. Discussion/Other Business

13. Adjourn

Gastroesophageal

Developing Studies

S2303, "Phase II/III Trial of Nivolumab + Cabozantinib or Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 5 Advanced Gastric and Esophageal Adenocarcinoma." Dr. Saeed.

Active Studies

CTSU/A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/2022.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/2020.

Pancreatic

Developing Studies

S2411, "A Randomized Phase II Study of Neoadjuvant Nadunolimab + FOLFIRINOX vs Cemiplimab + Motixafortide + FOLFIRINOX vs

Gastrointestinal Committee

CTSUNRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

CTSUEA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

CTSUEA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Dr. Stein. Activated: 1/31/20. Permanently Closed: 03/22/2023.

Colorectal

Active Studies

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" SWOG Champion: S. Gholami Activated: 1/10/23.

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Dr. Morris. Activated: 6/06/22.

CTSUNRG-GI008, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) SWOG GI Committee Co-Chairs: P. Philip & C. Eng Activated: 03/10/2022

CTSUNRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. Scott. Activated: 12/16/19.

CTSUNRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17.

Closed Studies

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP)

Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Raghav. Activated: 10/19/17. Step 1 closed to accrual: 1/1/2022.

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Zell. Activated: 3/1/13. Permanently Closed: 6/30/2023

CTSUA021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Dr. Lieu. Activated: 9/12/17. Permanently Closed: 01/17/2023

CTSUA021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Dr. Cohen. Activated: 9/30/19. Permanently Closed: 12/15/2022.

Anal

Active Studies

A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer" Activated 11/9/2022. SWOG Champion: A. Dasari

CTSUEA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

CTSUEA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

CTSUEA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Dr. Cho. Activated 5/13/21.

Other

Developing Studies

S2408, "A Randomized Phase III Multicenter Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula" Dr. Sham, Submitted to DCP 7/28/2023.

Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1613	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806
Ascension Providence Hospitals - Southfield	-	-	2	-	-	3	-	-	-
Banner University Medical Center - Tucson	-	-	-	3	-	2	3	-	1
Baptist Memorial Health Care/Mid South Minority Underserved	-	-	2	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	1	-
Boston Medical Center	-	-	-	-	-	1	3	-	1
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	6	-	-	2
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	2	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	1	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	2	-	-	-	1	-	-
Columbia University Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	4	-	-	1
Hawaii Minority Underserved NCORP	1	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	3	-	-	-	3	-	-	-	-
Henry Ford Hospital	-	-	1	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	-	-	-	3	17	-	-	-
Lahey Hospital and Medical Center	1	-	-	-	-	-	-	-	-
Loyola University Medical Center	1	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	1	2	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	4	-	-
Montana Cancer Consortium NCORP	-	-	-	-	1	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	9	1
Northwestern University LAPS	1	1	-	-	-	1	-	8	-
Oregon Health and Science University	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	3	-	-	1	2	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1613	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806
Southeast Clinical Oncology Research Consortium NCORP	1	-	2	2	2	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	3	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	2
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	-	-	-	-	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	1	-	-	-	-	2	-	1	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	3	-
University of Colorado Cancer Center LAPS	1	-	2	-	-	6	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	3	-	1	-
University of Kentucky/Markey Cancer Center	-	-	-	3	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	1	3	2	1	-	-	2	-	4
University of Rochester LAPS	-	1	-	-	-	2	8	-	6
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	-	3
University of Texas MD Anderson Cancer Center LAPS	13	9	-	-	4	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	1	2	-	-	-	-	-
University of Wisconsin Carbone Cancer Center	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	3	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	4	2	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	-	-	2	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	4	-	8	1
ALLIANCE	6	9	5	-	4	-	-	-	-
ECOG-ACRIN	4	1	6	2	2	-	-	-	-
NRG	5	2	3	4	4	-	-	-	-
Total	54	28	37	19	28	68	23	32	22

Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A022102	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGGI004
Ascension Providence Hospitals - Southfield	-	-	-	1	2	2	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	-	-	-	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	2	-	2	-	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	2	-	2	1	3	-	-	-
Cancer Research Consortium of West Michigan	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	2	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	1	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	1
Kaiser Permanente NCORP	-	-	-	4	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	2	-	-	-	-
Northwestern University LAPS	-	-	-	1	-	1	-	-	-	-
Oregon Health and Science University	-	-	-	2	1	-	-	1	3	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
STCC at DHR Hlth Inst for Res & Dev	-	-	-	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A022102	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGGI004
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	1	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	2	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-	-	-	-	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	2	-	2	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	1	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	1	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	5	2	-	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	7	-	-	-	-	-	12
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
University of Wisconsin Carbone Cancer Center	-	-	-	-	-	-	-	-	-	1
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	1	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	2	3	6	19	8	23	7	1	4	15

Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGGI005	NRGGI008		NRGGI005	NRGGI008
Ascension Providence Hospitals - Southfield	5	1	Southeast Clinical Oncology Research Consortium	-	-
Banner University Medical Center - Tucson	-	-	Sutter Cancer Research Consortium	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	3	1	The Don and Sybil Harrington Cancer Center	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	The West Clinic - Wolf River	-	1
Boston Medical Center	-	-	UC Davis Comprehensive Cancer Center LAPS	1	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	UC Irvine Health/Chao Family Comprehensive Cancer Cntr	1	-
Cancer Research Consortium of West Michigan	-	-	USC Norris Comprehensive Cancer Center LAPS	-	-
Carle Cancer Cntr NCI Comm Oncology Research Program	-	-	University of Arkansas for Medical Sciences	-	-
City of Hope Comprehensive Cancer Center	-	-	University of Cincinnati Cancer Center-UC Medical Center	-	-
Columbia University Minority Underserved NCORP	-	-	University of Colorado Cancer Center LAPS	-	1
CommonSpirit Health Research Institute	-	-	University of Kansas Cancer Center - MCA Rural MU NCORP	2	-
Dayton NCI Community Oncology Research Program	1	-	University of Kentucky/Markey Cancer Center	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	University of Michigan Comprehensive Cancer Center LAPS	-	-
Hawaii Minority Underserved NCORP	-	-	University of Rochester LAPS	-	-
Heartland Cancer Research NCORP	-	-	University of Texas Health Science Center at San Antonio	-	-
Henry Ford Hospital	1	-	University of Texas MD Anderson Cancer Center LAPS	1	-
Houston Methodist Hospital	-	-	University of Utah - Huntsman Cancer Institute LAPS	-	-
Kaiser Permanente NCORP	11	-	University of Wisconsin Carbone Cancer Center	-	-
Lahey Hospital and Medical Center	-	-	Vanderbilt University - Ingram Cancer Center LAPS	1	1
Loyola University Medical Center	-	-	Virginia Mason Medical Center	-	-
Medical U of South Carolina Minority Underserved	-	-	Wayne State University - Karmanos Cancer Institute LAPS	-	-
Michigan Cancer Research Consortium NCORP	1	-	William Beaumont Hospital-Royal Oak	-	-
Moffitt Cancer Center	-	-	Wisconsin NCI Community Oncology Research Program	-	-
Montana Cancer Consortium NCORP	-	-	Yale University - Yale Cancer Center LAPS	4	-
Northwell Health NCORP	1	1	ALLIANCE	-	-
Northwestern University LAPS	-	-	ECOG-ACRIN	-	-
Oregon Health and Science University	1	-	NRG	-	-
Pacific Cancer Research Consortium NCORP	-	-	Total	35	6
STCC at DHR Hlth Inst for Res & Dev	1	-			

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS

Scientific Leadership

Translational Medicine: David J. McConkey, PhD (GU Chair)
 Joshua J. Meeks, MD, PhD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta "Monty" K. Pal, MD (Renal)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Immunotherapeutics: Shuchi Gulati, MD
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Neeraj Agarwal, MD
 Bladder Organ Site Chairs: Seth P. Lerner, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Daniel P. Petrylak, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Peter J. Van Veldhuizen, Jr., MD
 DEI Champion: Jessica D. McDermott, MD
 Digital Engagement: Neema Navai, MD
 Veterans Affairs: Michael M. Goodman, MD
 Data Coordinators: Jeri Jardine, BA
 Laura Wells, BA
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRAs: Abigail L. Cornette, MS
 Cheryl Farlow, RN, OCN
 Nurse: Cheryl Kefauver, RN
 Patient Advocates: Rick Bangs, MBA (Emeritus)
 Darrell Nakagawa (Bladder)
 Tony Crispino (Emeritus)
 Karen Costello, MSS, LSW (Prostate)
 Laura B. Esfeller, MA (Renal)

Pharmaceutical Science: Joyce Lee, PharmD
 Allison Schepers, PharmD
 Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Saturday, October 14, 2023 10:15 a.m. - 12:15 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

10:15 - 10:30 am: Chair's Welcome and Opening Remarks
 Seth Lerner (by Zoom)
 10:30 - 11:15 am: Cancer Control - Dr. Peter Van Veldhuizen
 11:15 - 12:15 pm: Review of open approved trials - all organ site chairs

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak
 Daneshmand (Local).

Priority Study

S2011, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Temporary Closure: 7/11/23.

Concepts in Development

XXXX, "Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (PRESERVE)." Dr. L. Ballas. Submitted to GU Bladder Task Force 2/21/23.

Active Studies

S1937, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19.

Genitourinary Committee

CTSUA031701, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSUA031803, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSEAE8185, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

CTSEAE8192, "A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy" Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

Closed Studies

S1011, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

S1602, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

XXXXX, "Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]." Drs. P. Barata and U. Vaishampayan. Resubmitted to GU Renal Task Force 7/12/23 for 7/26/23 review.

Active Studies

S2200, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)" Drs. B. Maughan and S. Pal. Activated 9/19/22.

CTSUAREN1721, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

CTSU/A031704, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

Genitourinary Committee

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14.

Concepts in Development

S2312, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Submitted to GUSC to address Round 2 of comments 9/6/23.

Active Studies

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RTOG-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial." Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized

Genitourinary Committee

Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I).” Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, “A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.” Dr. A. D’Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Translational Medicine

Chair: Dr. David McConkey

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta “Monty” Pal

Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

Active Studies

S1600, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

S1823, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/2020 GU Champions: Thomas Frye & Anishka D’Souza

S1931 (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

S1937 (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1

Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937

Diverse Studies of Interest

S1609, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, “A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)” Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

CTSU/EAY 131, “Molecular Analysis for Therapy Choice (MATCH).” Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol Z1G reactivated: 2/23/22

CTSU/EA8134, “InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).” Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	A031102	A031701	A031702
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	6	-	1	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	2	3	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	6	-
Cancer Research Consortium of West Michigan NCORP	2	5	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	4	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	6	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	9	2	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	1	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	3	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	1	-	-	-	-	-	-	-
Desert Regional Medical Center	1	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	17	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	75	66	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	3	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	8	8	1	-	3	1	-	1	-
Henry Ford Hospital	23	4	-	1	-	-	-	-	2
Instituto Nacional De Cancerologia	1	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	1	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	16	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	6
Loyola University Medical Center	9	5	1	2	-	-	-	-	1
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	5	-	-	1	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	7	18	-	2	-	1	-	-	-
Montana Cancer Consortium NCORP	3	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	10	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	1
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-
Northwestern University LAPS	-	8	1	-	-	-	-	-	-

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	A031102	A031701	A031702
Ohio State University Comprehensive Cancer Center LAPS	2	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	1	-	-	-	1	-	-	4
SCL Health Saint Joseph Hospital	2	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	8	1	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-
Tulane University Health Sciences Center	-	-	9	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	12	9	2	3	-	-	-	9	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	6	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	3	3	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	2	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	-	3	-	-	12	-	4
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	-	2	-	-	-	-	-	1
University of Arkansas for Medical Sciences	2	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	6	5	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	4	5	-	3	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	7	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	3	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	-	13	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	-	-	-	-	1
University of Oklahoma Health Sciences Center LAPS	27	15	4	-	-	1	-	-	-
University of Rochester LAPS	23	-	1	-	-	-	-	-	3
University of Texas Health Science Center at San Antonio	7	-	2	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	79	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	1	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	2	2	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	3	4	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	1	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	10	6	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	3	-	-	-	-	-	-	-
ALLIANCE	95	27	3	1	-	-	-	-	-
ECOG-ACRIN	78	34	6	2	1	-	-	-	-
NRG	84	118	6	1	-	-	-	-	-
Total	696	411	63	23	5	4	12	16	24

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A031704	A031801	A031803	A031901	A031902	A032001	A032101	EA8134	EA8171
Ascension Providence Hospitals - Southfield	2	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	1	-	-	-	-	-	46
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	4	6	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	14	-	-	-	-	-	11
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	2
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	6	-	-	2	-	-	-	-	1
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	56	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	1	-	-	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	1	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	1	-	-	-	-	-	-	-	-
Northwestern University LAPS	2	-	-	-	-	-	1	-	-

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A031704	A031801	A031803	A031901	A031902	A032001	A032101	EA8134	EA8171
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	5	-	-	-	-	-	-	-	12
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-
Tulane University Health Sciences Center	1	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	3	7	5	-	-	2	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	9	-
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	1	7	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	5	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	11	-	-	-	-	-	1	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	7	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	6	-	-	-	-	-	13
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	-	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	110	10	36	2	5	8	2	10	85

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA8183	EA8185	EA8191	EA8192	EA8212	NRGGU002	NRGGU005	NRGGU008
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	2	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	11	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	25	1	1	4
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	1	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	1	-
Northwell Health NCORP	-	-	-	-	-	-	-	1
Northwestern University LAPS	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA8183	EA8185	EA8191	EA8192	EA8212	NRGGU002	NRGGU005	NRGGU008
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	5	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	2	-
Tulane University Health Sciences Center	-	-	-	-	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	1
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	2	-	1	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	2	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	3	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
Total	4	1	19	2	28	4	9	7

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGGU009	NRGGU010	NRGGU011
Ascension Providence Hospitals - Southfield	-	-	-
Audie L Murphy VA Hospital	-	-	-
Banner MD Anderson Cancer Center	-	-	-
Banner University Medical Center - Tucson	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-
Gulf South Minority Underserved NCORP	9	-	1
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Instituto Nacional De Cancerologia	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Hospital and Medical Center	-	-	-
Loyola University Medical Center	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Mercy Medical Center - Des Moines	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-
New Mexico Minority Underserved NCORP	-	-	-
Northwell Health NCORP	2	1	-

Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGGU009	NRGGU010	NRGGU011
Northwestern University LAPS	-	4	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	-	-
SCL Health Saint Joseph Hospital	-	3	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	-	-	-
Tulane University Health Sciences Center	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-
University of Colorado Cancer Center LAPS	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	1	-
University of Mississippi Medical Center	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	-	2	-
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Virginia Mason Medical Center	3	2	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-
Western States Cancer Research NCORP	1	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	17	13	1

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chi-An Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 Data Coordinator: Matt Gospe
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Chris Kippola
 Clinical Trial Program Manager: Laura Gildner, MS

Time/Location

Thursday, October 12, 2023 1:00 p.m. - 3:00 p.m.
 Room: Crystal C (Lobby Level, West Tower)

Agenda

- 1:00 – 1:20 pm** **S2101 iMATCH Pilot – Trial Update**
 Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan

- 1:20 – 2:00 pm** **SITC’s Resistance Data Collection Effort, led by SITC’s
 Immunotherapy Resistance Committee**
 Hussein Tawbi, MD, PhD
 Deputy Chair, Dept of Melanoma Medical Oncology
 Co-Director, MD Anderson Brain Metastasis Clinic

- 2:00 – 2:15 pm** **How to Navigate Clinical Data Resources for IO
 Studies and Secondary Analyses**
 Megan Othus, PhD
 Professor, Biostatistics and Biomathematics
 Public Health Sciences Division, Fred Hutch

- 2:15 – 2:20 pm** **Q & A**

- 2:20 – 3:00 pm** **Immunotherapy in Breast Cancer**
 Marleen Kok, MD, PhD
 Netherlands Cancer Institute

Active Study

S2101, “Biomarker Stratified CaboZantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.” Drs. Hu-Lieskovan, Swiecicki and Politi.
 Activation: 10/14/22.

Immunotherapeutics Committee

**Accrual from trial opening through 6/30/2023
 by Institution and Study**

	S2101
<i>Essentia Health NCI Community Oncology Research Program</i>	1
<i>Heartland Cancer Research NCORP</i>	1
<i>New Mexico Minority Underserved NCORP</i>	1
<i>Northwestern University LAPS</i>	1
<i>Pacific Cancer Research Consortium NCORP</i>	1
<i>University of Michigan Comprehensive Cancer Center LAPS</i>	9
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	5
ALLIANCE	4
ECOG-ACRIN	3
NRG	1
Total	27

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS

Scientific Leadership

Translational Medicine: Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Cytogenetics Liaison: Min Fang, MD, PhD

Designates

Cancer Control: Stephanie B. Tsai, MD
 Data Coordinators: Louise Highleyman, BA
 Matt Gospe, BS
 Oncology Research Professionals:
 CRA: Heather A. Thulean, BS
 Nurse: Natalie C. Sikes, MSN, RN
 Patient Advocate: Gail Sperling, MPH
 Pharmaceutical Science: Holly O. Chan, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Sharon Palmer
 Protocol Project Manager - MyeloMATCH: Sarah Cantu
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Friday, October 13, 2023 4:30 p.m. - 6:30 p.m.
 Room: Regency C (Ballroom Level, West Tower)

Agenda

AML/MDS Studies

Active Studies

CTS/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Temporarily closed to accrual 11/19/2021

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Closed: 9/3/20.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

ALL Studies

Active Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20. Temporarily closed to accrual: 12/23/22.

CTS/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 05/24/22.

Developing Studies

S2306, "A Randomized Phase 2 Trial to Evaluate the Efficacy of Bcl-2 Inhibitor Therapy with Chemotherapy Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma." Drs. K. O'Dwyer, I. Aldoss, A. Advani, and W. Stock.

S2307, "A Phase 1B Study Assessing the Safety and Activity of SNDX-5613 (revumenib) in Combination with Age-Modified Chemotherapy in Newly Diagnosed patients with KMT2Ar acute lymphoblastic leukemia (ALL) or acute leukemia with ambiguous lineage (ALAL)." Drs. I. Aldoss, A. Advani, W. Stock, and C. Saygin.

Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/01/09.

Leukemia Committee

S1312, “A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt’s Leukemia).” Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, “A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF).” Drs. A. Advani and K. O’Dwyer. Activated: 1/12/15; Closed: 4/15/21.

CLL Studies

Active Studies

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study.” Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Closed Studies

CTSU/EA9161, “A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).” Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSU/A041702, “A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL).” Dr. B. Hill. Activation: 1/4/19. Closed: 01/04/19.

CML Studies

Closed Studies

S1712, “A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease.” Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MyeloMATCH

Proposed Studies

MYELOMATCH, “Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials.” Drs. J. Radich and S. Jiwani.

MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial.” Drs. P. Shami and T. Lin.

MM10A-S02, “A Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor C-DEC (ASTX727) for the Treatment of TP53-Mutated Acute Myeloid Leukemia: A myeloMATCH treatment trial.” Drs. R. Shallis, D. Sallman, and A. Zeidan.

MM10A-S03, “A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Treatment Trial.” Drs. U. Borate and E. Huselton.

Leukemia Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1712	S1905	S1925	A041501	A041701	A041702	A041703	EA9152	EA9171	EA9181	EA9213
Banner University Medical Center – Tucson	-	-	-	-	-	5	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	1	-	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	5	4	-	5	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	1	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	3	1	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	1	-	-	-	-	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	1	3	1	-	-	-	-	-	-	-	1
Hawaii Minority Underserved NCORP	6	-	-	-	-	-	-	-	-	3	-
Heartland Cancer Research NCORP	5	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	2	-	4	3	-	-	-	-	-
Intermountain Medical Center	-	-	-	2	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	-	-	-	-	8	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	1	-	-	-	-	-
Loyola University Medical Center	1	-	1	-	-	1	-	-	-	1	-
Med Univ of South Carolina MU-NCORP	-	-	3	-	-	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	5	-	-	1	-	-	-	-	-
Moffitt Cancer Center	16	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	2	-	-	-	-	3	-	-	-	-	-
New Mexico Minority Underserved NCORP	3	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	2	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	3	1	2	-	-	-	4	-
Oregon Health and Science University	3	1	-	8	-	5	-	-	-	-	-
STCC at DHR Hlth Inst for Res & Dev	-	-	1	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	1	-	-	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	8	-	11	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	2	2	-	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	-	-	3	-	-	-	-	-	8	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-	1	-
U of Alabama at Birm/Deep South Res Consort LAPS	-	-	-	1	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	4	-	-	-	-	-	-
U of Cincinnati CC-UC Med Ctr	-	2	-	-	-	-	1	-	-	1	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	1	-	-	-	-	-
U of Kansas CC-MCA Rural MU-NCORP	-	-	-	-	-	6	-	-	-	-	-
University of Rochester LAPS	7	1	7	7	27	1	3	-	-	6	-
University of Utah - Huntsman Cancer Institute LAPS	7	-	12	1	-	5	-	-	-	-	-
Wayne State Univ-Karmanos Ca Inst LAPS	-	-	-	-	-	-	-	-	-	3	-
Western States Cancer Research NCORP	-	-	-	-	-	2	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	5	-	3	-	1	2	1	-
ALLIANCE	13	2	15	-	-	-	-	-	-	-	-
CCTG	-	-	3	-	-	-	-	-	-	-	-
ECOG-ACRIN	7	-	9	-	-	-	-	-	-	-	-
NRG	2	-	2	-	-	-	-	-	-	-	-
Total	81	13	72	44	38	65	4	1	2	29	1

FRIDAY, OCTOBER 13 • 10:15 – 11:45 PM CT
REGENCY A (BALLROOM LEVEL, WEST TOWER)

Learn the latest on the Lung Master Protocol

Lung-MAP

Update Meeting

NCI National Clinical Trials Network

S1900E

For Patients With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small-Cell Lung Cancer

Clinical trial summary (S1900G)

Combining Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes

What is the purpose of this clinical trial?

LUNG-MAP
A lung cancer precision medicine trial

VOLUME 23 | SUMMER 2023 | NEWSLETTER | WWW.LUNG-MAP.ORG

S1900G Is Open and Enrolling:

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non-small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types.

METHODS In this randomized phase II Lung-MAP normatch substudy (S1800A), patients ineligible for a biomarker-matched substudy with NSCLC previously treated with ICI and platinum-based chemotherapy and progressive disease at least 84 days after initiation of ICI were randomly assigned to receive ramucirumab plus pembrolizumab (RP) or investigator's choice standard of care (SOC: docetaxel/ramucirumab, docetaxel, gemtuzumab, and pemetrexed). With a goal of 130 eligible patients, the primary objective was to compare overall survival (OS) using a one-sided 10% level using the better of a standard log-rank (SLR) and weighted log-rank (WLR; G₀ = 0, gamma = 1) test. Secondary end points included objective response, duration of response, investigator-assessed progression-free survival, and toxicity.


RESULTS Of 166 patients enrolled, 136 were eligible (69 RP, 67 SOC). OS was significantly improved with RP (hazard ratio [95% CI]: 0.69 [0.51 to 0.92]; SLR one-sided P = .05; WLR one-sided P = .15). The median (95% CI) OS was 14.5 (13.9 to 15.1) months for RP and 11.6 (9.9 to 13.0) months for SOC. OS benefit for RP was seen in most subgroups. Investigator-assessed progression-free survival (hazard ratio [95% CI]: 0.86 [0.66 to 1.14], one-sided SLR P = .25 and 1.4 for WLR) and response rates (22% RP vs 28% SOC, one-sided P = .19) were similar between arms. Grade ≥ 3 treatment-related adverse events occurred in 42% of patients in the RP group and 60% on SOC.

CONCLUSION This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy. The safety was consistent with known toxicities of both drugs. These data warrant further evaluation.

ASCO | **Journal of Clinical Oncology**

The session will include presentations on

- **Lung-MAP accomplishments and publications**
- **Accrual and enrollment representativeness**
- **Current sub-studies**
 - S1900E: looking ahead
 - S1900G: screening patients for MET amplification
- **Imminent sub-studies**
 - S1900J: NSCLC with MET amplification
 - S1900K: NSCLC with METex14-skipping mutation
- **Lung-MAP's future**
 - Expanding NGS profiling
- **Committee progress**
 - Translational Medicine Committee
 - Drug Selection Committee
 - Accrual Enhancement Committee



The Lung-MAP leadership encourages all who work with lung cancer research to attend!

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 Jieling Miao, MS
 James Moon, MS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Wayne L. Hofstetter, MD
 Raymond Osarogiagbon, MD
 Locally Advanced Disease: Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Ross Camidge, MD
 Karen Reckamp, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 DEI Champion: Lucy Gansauer, MSN, RN, OCN, CCRP
 Veterans Affairs: Chao H. Huang, MD
 Cheryl M. Czerlanis, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pazarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurse: Rosalie Zablocki, RN
 Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Kimberly McConnell, PharmD

Protocol Project Managers: Justine Trevino
 Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, October 14, 2023 9:15 a.m. - 12:15 p.m.
 Room: Regency C (Ballroom Level, West Tower)

Agenda

9:15 - 9:20 am General Update: Jhanelle E. Gray, MD
 9:20 - 9:25 am Patient Advocate Update: Judy Johnson, MBA
 9:25 - 9:30 am Thoracic Surgery Session: Eric Toloza, MD, PhD
 9:30 - 9:35 am Thoracic Radiation Session: Megan Daly, MD
 9:35 - 9:40 am Translational Medicine Session: Philip C. Mack, PhD
 9:40 - 9:45 am Community Engagement Core: Paul J. Hesketh, MD
 9:45 - 9:50 am DEI Session: Lucy Gansauer, MSN, RN
 9:55 - 10:05 am Speaker: AEGEAN Trial - John V. Heymach, MD, PhD
 Chair, Thoracic/Head & Neck Medical Oncology, The University of Texas
 MD Anderson Cancer Center
 10:05 - 10:30 am Debate Panel: Is Neoadjuvant Chemo-IO better than
 Adjuvant Chemo-IO?
 Pro-Neoadjuvant Chemo-IO: speaker TBA
 Pro-Adjuvant Chemo-IO: Barry Gibney, DO
 Moderator: Jhanelle E. Gray, MD
 10:30 - 11:30 am Thoracic Medical Oncology Session: Jhanelle Gray, MD
S2302, "Project Pragmatica-Lung Trial." Dr. Karen Reckamp**. Activated:
 3/6/23; Accrual: 112.
LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies
 and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
 (Lung- Map Screening Study)." Drs. Karen Reckamp and David Gandara
 (SWOG). Activated: 1/28/19; Accrual: 3154.
S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with
 Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-
 Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-
 STUDY)." Dr. Karen Reckamp (SWOG). Dr. Suki Padda and Dr. David Gerber
 (ECOG). Activated: 4/2/21; Accrual:98.

Lung Committee

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)". Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG). Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 5.

EA5182, "Randomized Phase III Study of Combination Osimertinib and Bevacizumab Versus Osimertinib Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant NSCLC". Dr. Sarah Goldberg (SWOG). Activated: 10/22/20; Accrual: 125.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)". Dr. Chad Rusthoven (SWOG). Activated: 1/10/20; Accrual: 171.

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Dr. Raid Aljumaily (SWOG). Activated: 6/15/20; Accrual: 30.

S1914, "A Randomized Phase III trial of Induction/Consolidation Atezolizumab +SBRT versus SBRT Alone in High risk, Early Stage NSCLC." Dr. Megan Daly (SWOG). Activated: 3/25/20; Accrual: 247.

EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Anne Chiang (SWOG). Activated: 2/28/19; Accrual: 555 total; 73.

11:05 - 11:30 am Open Discussion

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21.

S1900G, "A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S2302, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev. Activation: 3/6/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHE-MIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14.

Lung Committee

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated:10/22/20.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SFLN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

NCI-Approved Concepts

S1900J, "A Phase II Study of Amivantamab-vmjw in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le.

Lung Committee

S2313, "Neoadjuvant chemo-durvalumab for clinical stage I, 2-3.9cm, non-small cell lung cancer: a randomized controlled trial." Drs. Gibney and Wrangle.

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

S2409, "PRISM: A Multicohort PReclision SCLC Subtype Maintenance Phase II Trial of Durvalumab Ver-sus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Chiang and Chiappori.

S2410, "A randomized phase II study of a PDL1 inhibitor and iadademstat (ORY-1001) versus investigator's choice of standard of care for second line treatment of extensive stage small cell lung cancer (SCLC)." Drs. Santana-Davila and Puri.

Concepts in Development

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li.

S1900L, "A Randomized Phase II Study of Pembrolizumab and Ramucirumab with or without Tusamitamab-Ravtansine in CEACAM5 Expressing Previously Treated Stage IV or Recurrent NSCLC (Lung-MAP Sub-Study)." Drs. Judd and Petty.

Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929
Ascension Providence Hospitals - Southfield	13	-	-	-	-	-	-	3
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	35	-	-	2	1	-	6	2
Baylor College of Med/Dan L Duncan CCC	-	-	-	1	-	-	-	-
Boston Medical Center	-	-	-	5	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	-	-	2	-	-	-
Cancer Research Consortium of West Michigan NCORP	3	-	-	-	-	-	2	-
Cancer Research for the Ozarks NCORP	33	-	3	-	-	-	2	2
Ca Res of Wisconsin and N Mich Consort	25	-	2	-	3	-	2	-
Carle Cancer Center NCORP	2	1	-	1	-	-	6	-
Cedars-Sinai Medical Center	17	-	-	-	1	-	-	-
City of Hope Comprehensive Cancer Center	5	1	-	1	-	-	-	-
Columbia University Minority Underserved NCORP	9	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	27	-	-	3	-	-	-	-
CommonSpirit Health Research Institute	37	-	-	-	-	-	1	1
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	2
Essentia Health NCORP	16	-	2	-	-	-	2	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	-	1	-	-	2	3
Georgia NCI Community Oncology Research Program	58	-	4	2	1	-	6	-
Gulf South Minority Underserved NCORP	21	-	1	1	-	-	2	1
Hawaii Minority Underserved NCORP	25	-	-	1	-	-	-	-
Heartland Cancer Research NCORP	137	-	9	3	5	-	26	19
Henry Ford Hospital	7	-	-	-	-	-	-	1
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	1	-	-	-	-
Kaiser Permanente NCORP	78	-	6	-	8	-	2	-
Lahey Hospital and Medical Center	32	-	-	-	-	-	3	1
Loma Linda University Medical Center	6	-	-	-	-	-	-	-
Loyola University Medical Center	22	-	1	-	-	-	-	2
MAVERIC	59	-	3	3	1	-	-	-
Medical U of South Carolina Minority Underserved	15	-	1	-	1	-	-	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	1
Michigan Cancer Research Consortium NCORP	106	-	4	1	6	-	3	3
Mission Hospital	1	-	-	-	-	-	-	-
Moffitt Cancer Center	14	2	1	1	1	-	-	-
Montana Cancer Consortium NCORP	25	-	-	-	1	-	-	3
Mount Sinai Hospital	-	-	-	-	-	-	9	1
NCORP of the Carolinas (Prisma Health NCORP)	17	-	-	-	1	-	-	-

Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929
National Cancer Center-Korea	-	-	-	1	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	1
New Mexico Minority Underserved NCORP	79	-	-	1	2	-	6	5
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	26	1	2	1	-	-	-	4
Oregon Health and Science University	8	-	1	-	-	-	1	-
Pacific Cancer Research Consortium NCORP	15	-	-	-	-	-	-	3
SCL Health Saint Joseph Hospital	1	-	-	-	-	-	1	-
Salem Hospital	3	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	50	-	1	7	1	-	8	8
Sutter Cancer Research Consortium	24	-	-	-	1	-	-	-
The Don and Sybil Harrington Cancer Center	11	-	2	-	-	-	-	-
The J G Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	35	3	6	1	-	-	10	2
UC Irvine Hlth/Chao Family CCC	23	-	-	1	-	-	1	-
UC San Diego Moores Cancer Center	13	-	-	-	1	-	-	-
UPMC Hillman Cancer Center LAPS	58	-	5	5	6	-	-	3
USC Norris Comprehensive Cancer Center LAPS	-	-	-	3	-	-	5	-
University of Arkansas for Medical Sciences	11	-	1	-	-	-	7	-
U of Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	11	-	-	3	-	-	3	2
U of Kansas CC-MCA Rural MU-NCORP	89	-	1	1	1	-	-	-
University of Kentucky/Markey Cancer Center	50	-	-	1	-	-	-	-
University of Michigan Comprehensive Cancer Center	1	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	32	-	-	1	-	-	1	2
University of Rochester LAPS	63	-	2	-	6	-	3	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	1
University of Texas MD Anderson Cancer Center LAPS	3	6	-	-	-	-	-	4
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	3	-	-	2	1
Upstate Carolina NCORP	38	-	-	-	-	-	1	-
Wayne State Univ-Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	39	-	-	1	-	-	8	-
Yale University - Yale Cancer Center LAPS	23	-	-	3	3	-	4	-
ALLIANCE	750	3	15	15	17	1	25	9
CCTG	-	-	-	19	-	-	-	-
ECOG-ACRIN	340	3	5	7	18	-	18	10
NRG	399	1	4	52	7	1	44	6
Total	3,092	21	82	154	95	2	222	106

Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1933	S2302	A081801	A082002	A151216	A171901	E4512	EA5163
Ascension Providence Hospitals - Southfield	-	-	-	-	14	-	1	2
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	1	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	7	-	2	-
Baptist Mem Hlth Care/Mid South MU-NCORP	-	1	3	-	24	-	-	1
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	3	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	9	-	53	-	-	16
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	1	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	-	1	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	4	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	5	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	2	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	3	-	-	-
Dayton NCI Community Oncology Research Program	-	-	1	-	8	-	-	-
Essentia Health NCORP	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	15	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	9	-	-	1
Gulf South Minority Underserved NCORP	-	3	1	-	1	-	-	3
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	11	-	-	-	-	-	-
Henry Ford Hospital	-	-	2	-	29	-	-	-
Houston Methodist Hospital	-	-	-	-	8	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	3	3	-	201	-	3	8
Lahey Hospital and Medical Center	2	5	-	-	30	-	-	2
Loma Linda University Medical Center	-	-	-	-	9	-	-	-
Loyola University Medical Center	-	1	-	-	22	-	-	1
MAVERIC	-	-	10	-	31	-	-	3
Medical U of South Carolina Minority Underserved	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	3	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	14	-	83	-	1	-
Montana Cancer Consortium NCORP	1	-	-	-	-	-	-	-
Mount Sinai Hospital	-	1	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	1	-	-	-

Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1933	S2302	A081801	A082002	A151216	A171901	E4512	EA5163
National Cancer Center-Korea	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	1	-	-
New Mexico Minority Underserved NCORP	1	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	3	-	-	-
Northwestern University LAPS	-	3	-	-	-	-	-	-
Oregon Health and Science University	-	-	7	-	23	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	4	-	-	-
SCL Health Saint Joseph Hospital	-	-	1	-	3	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	1	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	1	11	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-
The J G Brown Cancer Center at University of Louisville	-	-	-	-	5	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	2	42	-	1	6
UC Irvine Hlth/Chao Family CCC	-	-	-	-	15	-	1	-
UC San Diego Moores Cancer Center	-	-	-	-	5	-	-	-
UPMC Hillman Cancer Center LAPS	2	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	12	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	2	-	-	1
U of Cincinnati CC-UC Med Ctr	-	-	-	-	22	-	1	1
University of Colorado Cancer Center LAPS	-	-	2	-	58	-	2	-
U of Kansas CC-MCA Rural MU-NCORP	-	-	1	-	30	-	-	6
University of Kentucky/Markey Cancer Center	-	-	-	-	5	-	-	-
University of Michigan Comprehensive Cancer Center	-	-	-	-	62	-	-	-
University of Mississippi Medical Center	-	-	-	-	26	-	-	-
University of Oklahoma Health Sciences Center LAPS	11	1	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	2
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	2
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	2	-	1	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	1
Upstate Carolina NCORP	-	-	-	-	-	-	-	-
Wayne State Univ-Karmanos Ca Inst LAPS	-	-	-	-	1	-	-	-
Western States Cancer Research NCORP	-	-	-	-	1	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	2	-	-	-
Wisconsin NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	5	-	54	-	4	12
ALLIANCE	5	5	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	5	-	-	-	-	-	-
NRG	1	3	-	-	-	-	-	-
Total	29	54	61	3	949	1	17	68

Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	NRGLU006	R1308
Ascension Providence Hospitals - Southfield	3	-	1	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	2	-	-
Banner University Medical Center - Tucson	10	-	-	-	-	1	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	1	1	-	-	1	4	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	2	-
Boston Medical Center	1	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	18	1	1	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Essentia Health NCORP	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	1	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	3	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	1
Loyola University Medical Center	2	-	-	-	-	-	-	-
MAVERIC	-	-	2	-	-	-	-	-
Medical U of South Carolina Minority Underserved	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
Mount Sinai Hospital	1	1	-	-	-	1	-	-

Lung Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	NRGLU006	R1308
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	3	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-
The J G Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	-	-	1	-	-
U of Cincinnati CC-UC Med Ctr	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	1	-	-
U of Kansas CC-MCA Rural MU-NCORP	-	-	3	-	-	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-	-	-	-	-
University of Rochester LAPS	17	-	-	4	-	1	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-
Wayne State Univ-Karmanos Ca Inst LAPS	-	-	-	-	1	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
Total	64	8	8	5	2	13	2	1

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Shay Bellasea, MS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Louis S. Constine, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Kambhampati, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
 Digital Engagement: Mazyar Shadman, MD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Nurse: TBD
 Patient Advocate: Hildy Dillon, MPH
 Pharmaceutical Science: Holly O. Chan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Katarina Gasic
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Friday, October 13, 2023 8:30 a.m. - 10:30 a.m.
 Room: Crystal A (Lobby Level, West Tower)

Agenda

Welcome and Introductions: Jonathan Friedberg, MD & Sonali Smith, MD

Spotlight on Relapsed DLBCL:

- | | | |
|----|-----------------------------|--------------|
| a. | New biologic observations | Dr. Hilton |
| b. | Current treatment landscape | Dr. Reagan |
| c. | S2207 | Dr. Amengual |

Review of Selected Studies:

- | | | |
|----|----------|--------------|
| a. | S2114 | Dr. Hess |
| b. | S1918 | Dr. Brem |
| c. | S1608 | Dr. Barr |
| d. | S1925 | Dr. Stephens |
| e. | EA4151 | Dr. Till |
| f. | AHOD2131 | Dr. Hu |
| g. | AO51902 | Dr. Amengual |
| h. | ANHL1931 | Dr. Kamdar |

Proposed Studies

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. Ghosh and Friedberg.

Active Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17.

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual, Reagan, and Smith. Activated: 6/30/2023

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Temporarily closed: 8/2/21.

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

Lymphoma Committee

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." Dr. Roth. SWOG Champion: Dr. Kamdar. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

Closed Studies

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

Open Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Re-lapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20. Temporarily closed: 12/23/2022.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.

Lymphoma Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1608	S1826	S1918	S2114	A051301	ANHL1931	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	-	1	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved	-	3	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	1	-	-	-	-
Boston Medical Center	-	3	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	15	14
Cancer Research Consortium of West Michigan NCORP	3	13	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	2	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	3	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	8	21	2	-	1	5	-	18	-
Columbia University Minority Underserved NCORP	-	2	2	-	-	-	1	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	4	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	3	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	14	-
Georgia Cares Minority Underserved NCORP	-	6	2	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	2	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	20	-	-	-	-	-	-	-
Henry Ford Hospital	-	8	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	11	2	-	-	-	11	-	13
King Faisal Specialist Hospital and Research Centre	-	-	-	-	4	-	-	-	-
Loyola University Medical Center	-	8	-	-	-	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	2	19	3	4	-	-	-	2	-
Michigan Cancer Research Consortium NCORP	1	6	4	-	-	-	-	-	-
Moffitt Cancer Center	-	15	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	-	-	2	-

Lymphoma Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1608	S1826	S1918	S2114	A051301	ANHL1931	E4412	EA4151	EA4181
Nevada Cancer Research Foundation NCORP	-	2	-	-	-	-	1	-	-
Northwestern University LAPS	1	-	-	-	-	1	-	-	-
Oregon Health and Science University	-	4	-	-	-	-	-	6	5
Pacific Cancer Research Consortium NCORP	-	7	-	1	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	6	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	18	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	1	-	-	1	-	-	-
UC San Diego Moores Cancer Center	-	8	-	-	-	-	-	1	-
U of Alabama at Birm/Deep South Res Consort LAPS	-	12	-	-	-	-	7	5	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	9	-	-	-	-	-	2	3
University of Colorado Cancer Center LAPS	-	4	-	-	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	1	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-	-
University of Rochester LAPS	14	33	-	1	3	3	-	10	17
University of Texas Health Science Center at San Antonio	-	17	-	-	-	-	-	12	-
University of Texas MD Anderson Cancer Center LAPS	3	34	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	14	2	-	-	-	-	18	12
Upstate Carolina Consortium Community Oncology Research Program	1	7	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	4	-	-	1	-	-	1	6
Wisconsin NCI Community Oncology Research Program	-	11	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	-	-	-	-	-	4	-
ALLIANCE	15	134	24	-	-	-	-	-	-
CCTG	-	30	-	-	-	-	-	-	-
COG	-	313	-	-	-	-	-	-	-
ECOG-ACRIN	5	83	10	-	-	-	-	-	-
NRG	11	51	3	-	-	-	-	-	-
Total	73	994	58	6	12	10	20	115	73

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Michael Wu, PhD
 Megan Othus, PhD
 James Moon, MS
 Hongli Li, MS

Scientific Leadership

Translational Medicine: William E. Carson, III, MD
 Radiation Oncology: Evan J. Wuthrick, MD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: Clara Curiel-Lewandrowski, MD
 Imaging: Ari M. VanderWalde, MD
 Medical Oncology: Sapna Pradyuman Patel, MD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: Jeffrey A. Sosman, MD
 SWOG's ECOG Liaisons: Thach-Giao Truong, MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Andrew Poklepovic, MD
 Digital Engagement: Zeynep Eroglu, MD

Designates

Cancer Control Liaison: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Data Coordinator: Matt Gospe, BS
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRA: Kathryn Allen, BA, CCRP
 Nurse: Lisa S. Morgan, RN, OCN
 Patient Advocate: Samantha Guild, J.D.
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, October 14, 2023 9:30 a.m. - 11:30 a.m.
 Room: Regency B (Ballroom Level, West Tower)

Agenda

Active Studies

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Temporarily Closed to Accrual as of 04/07/2023

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015.

CTSU/EA6192, "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020.

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022.

Closed Studies

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

Melanoma Committee

S1616, “A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, “A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPH Activated: 02/18/2020. Closed: 09/23/2022.

Studies in Development

S2305, “Phase II Study of the Triplet Combination of Relatlimab, Nivolumab, and Ipilimumab for Melanoma with Prior Progression on Immune Checkpoint Inhibitor Therapy” Drs. Naing and Patel

S2412, “Phase III Study of Neoadjuvant/Adjuvant Pembrolizumab versus Adjuvant Pembrolizumab in Resectable Melanoma” Drs. Sharon and Patel

Melanoma Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1801	S2000	S2015	A091903	EA6141	EA6174	EA6192
Banner MD Anderson Cancer Center	3	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	-	-	-	3	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	1	-	-	-	-	-	-
Boston Medical Center	1	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	16	-
Cancer Research Consortium of West Michigan NCORP	26	-	43	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	1	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	2	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	7	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	3	-	-
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	-	2	-	-
Duke University - Duke Cancer Institute LAPS	-	-	2	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	1	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	1	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	6	-	-	-	-	-	-
Intermountain Medical Center	-	-	1	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	14	-	-	-	25	-	-
Loma Linda University Medical Center	2	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	5	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	5	-	-	-	-
Michigan Cancer Research Consortium NCORP	5	-	-	-	-	-	-
Moffitt Cancer Center	-	15	17	-	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	1	-	-	-	-	-	-

Melanoma Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1801	S2000	S2015	A091903	EA6141	EA6174	EA6192
Northwell Health NCORP	7	-	-	-	-	-	-
Northwestern University LAPS	13	-	20	-	1	1	5
Ohio State University Comprehensive Cancer Center LAPS	13	1	10	-	-	3	3
Pacific Cancer Research Consortium NCORP	3	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	1	-
Sutter Cancer Research Consortium	-	-	-	-	5	1	-
The Don and Sybil Harrington Cancer Center	3	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	3	-	-	-	4	8	-
UCLA / Jonsson Comprehensive Cancer Center	6	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	1	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	8	-	-	1	-	3	-
University of Alabama at Birmingham / Deep South Research Consortium	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	3	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	2	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	8	-	17	-	-	1	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	15	2	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-
University of Rochester LAPS	4	-	2	-	2	1	-
University of Texas Health Science Center at San Antonio	-	-	-	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	10	-	6	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	20	-	11	-	-	8	-
Western States Cancer Research NCORP	-	-	-	-	1	-	-
Wisconsin NCI Community Oncology Research Program	9	-	3	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	9	-	6	1	-
ALLIANCE	32	1	14	-	-	-	-
ECOG-ACRIN	50	4	54	-	-	-	-
NRG	47	1	18	-	-	-	-
Total	345	28	245	1	53	53	8

Radiation Oncology Committee

Leadership

Chair.....Chul Ha, MD
 Vice-Chair Lisa Kachnic, MD
 Executive Officer..... Lisa Kachnic, MD
 Statistician..... Danika Lew, MA

Designates

Breast Committee liaison Reshma Jagsi, MD, DPhil
 Cancer Care Delivery Committee liaison Eileen Connolly, MD
 Cancer Control & Prevention Committee liaison Eileen Connolly, MD
 CNS Working Group liaison Tony Wang, MD
 Genitourinary Committee liaison James Yu, MD
 Gastrointestinal Committee liaison David Horowitz, MD
 Lung Committee liaison Henry Park, MD
 Lymphoma Committee liaison..... Sandy Constine, MD
 Melanoma Committee liaison..... Evan Wuthrick, MD

Time/Location

Friday, October 13, 2023 3:00 pm-5:00 pm
 Room: Comiskey (Concourse Level, West Tower)

Agenda

3:00 - 3:05 pm Welcome Chul S. Ha, MD
 3:05 - 3:10 pm Report from Executive Officer Lisa Kachnic, MD
 3:10 - 3:55 pm Keynote Lecture: New Paradigms for Image Based
 Response Assessment: Lawrence Schwartz, MD
 3:55 - 4:45 pm Reports by Committees

Breast

Report by liaison: Reshma Jagsi, MD, DPhil

S1706: A phase II randomized trial of olaparib administered concurrently with RT vs RT alone for inflammatory breast cancer. Reshma Jagsi, MD, DPhil

Randomized phase III trial of multimodality therapy in each subtype of stage IV oligometastatic breast cancer vs palliative therapy (under development). Shane Stecklein, MD, PhD

Re-radiation trial for in-breast recurrence (under development). Eileen Connolly, MD

CDK 4/6 inhibition concurrent with RT for ER+ locally advanced breast cancer (under development). Corey Speers, MD, PhD

CNS

Report by liaison: Tony Wang, MD

Phase II study of atezolizumab and tocilizumab with radiotherapy in patients with newly diagnosed MGMT unmethylated glioblastoma (under development). Tony Wang, MD

Gastrointestinal

Report by liaison: David Horowitz, MD

Phase II anal cancer protocol under development. David Horowitz, MD

Genitourinary

Report by liaison: James Yu, MD

Lung

Report by liaison: Henry Park, MD

S1914: A randomized phase III trial of induction/consolidation Atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC. Megan Daly, MD

S1933: A pilot study of hypofractionated radiotherapy followed by atezolizumab consolidation in stage II or III NSCLC patients with borderline performance status. Raid Aljumaily, MD

S1827: MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation: a randomized phase III trial in small-cell lung cancer. Chad Rusthoven, MD

NRG CC009: Phase III trial of SRS versus hippocampal-avoidant whole brain radiotherapy for 10 or fewer brain metastases from small cell lung cancer. Chad Rusthoven, MD

Sequencing of immunotherapy and chemotherapy in unresectable stage III non-small cell lung cancer. Henry D. Park, MD, MPH

Lymphoma

Report by liaison: Sandy Constine, MD

Melanoma

Report by liaison: Evan Wuthrick, MD

Secondary analysis for S1404. Evan Wuthrick, MD

Sarcoma

S2310: Phase II Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk, Resectable Sarcoma. Jeremy Harris, MD

Radiation Oncology Committee

Cancer Control & Prevention Committee/ Cancer Care Delivery Committee

Report by liaison: Eileen Connolly, MD

S2304: A phase II randomized trial of intraoperative radiotherapy (IORT) vs. no IORT for postmenopausal women with low-risk ductal carcinoma in situ after breast conserving therapy (under development). Eileen Connolly, MD

4:35-4:40 pm Announcements

Search for liaisons for Cancer Survivorship Committee, Symptom Control & Quality of Life Committee, Immunotherapeutics Committee, and Early Therapeutics & Rare Cancer Committee.

Time for monthly calls

4:40-4:55 pm Open Forum

4:55-5:00 pm Closing remarks Chul S. Ha, MD

Publication List by Committee

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the Spring 2023 Group Meeting. Conference abstracts are not included. Note: because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

BREAST COMMITTEE

Published/Accepted Manuscripts

S0221 Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. Cannioto R, Attwood K, Davis E, Mendicino L, Hutson A, Zirpoli G, Tang L, Nair N, Barlow W, Hershman D, Unger J, Moore H, Issacs C, Hobday T, Hortobagyi G, Gralow J, Albain K, Budd GT, Ambrosone C. *JAMA Network Open* May 1;6(5):e2311673, 2023.
<https://pubmed.ncbi.nlm.nih.gov/37140922/>

S0221 Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in White and Black patients in SWOG S0221. Chen C, Zirpoli G, McCann S, Barlow W, Budd GT, Puzstai L, Henry NL, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Accepted 2023. [see also SCQL Committee]

S0221/Other Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) [SWOG collaborators: GT Budd, W Barlow, K Albain, J Gralow, D Hayes, R Jagsi]. *Lancet*. Apr 15;401(10384):1277-1292, 2023.
<https://pubmed.ncbi.nlm.nih.gov/37061269/>

S0226 Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, Dakhil SR, Tirumali NR, Gralow J, Hortobagyi GN, Puzstai L, Mehta RS, Hayes DF,

Kidwell KM, Henry NL, Barlow WE, Rae JM, Hertz DL. *Pharmacogenomics* Aug 24. doi: 10.2217/pgs-2023-0097. Online ahead of print, 2023. [see also Pharmaceutical Sciences Committee]
<https://pubmed.ncbi.nlm.nih.gov/37615099/>

S1007 Radiotherapy Use and Incidence of Locoregional Recurrence in Patients with Favorable-Risk Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein S, Zeidan Y, Zhang H, Sharma P, Puzstai L, Hortobagyi G, Kalinsky K. *JAMA Oncology*, Jul 6:e231984, 2023.
<https://pubmed.ncbi.nlm.nih.gov/37410451/>

S0800 Image analysis-based tumor infiltrating lymphocyte measurement predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800). Fanucci K, Blenman K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Puzstai L. *NPJ Breast Cancer* May 13;9(1):38, 2023.
<https://pubmed.ncbi.nlm.nih.gov/37179362/>

IBC24-02 Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperis A, Brown LC, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller B, Jochum W, Bonnefoi H, Martino S, Davidson NE, Geyer C, Chia SK, Ingle JN, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S. *Ann Oncol*. Apr;34(4):397-409, 2023.
<https://pubmed.ncbi.nlm.nih.gov/36709040/>

IBC48 Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruiz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjak S, Cardoso F, Smith KL, Ferreiro T, Ribí K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. *N Engl J Med*. May 4;388(18):1645-1656, 2023. [see also Cancer Survivorship Committee]
<https://pubmed.ncbi.nlm.nih.gov/37133584/>

Submitted Manuscripts

S9313 Dual Prognostic Classification of Triple-Negative Breast Cancer

Publication List by Committee

by DNA Damage Immune Response and Homologous Recombination Deficiency. Stecklein S, Barlow W, Puzstai L, Timms K, Kennedy R, Logan G, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Revised/resubmitted, 2023.

CANCER CONTROL AND PREVENTION COMMITTEES

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

S1204 Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients. Unger JM, Till C, Hwang JP, Arnold KB, Hershman DL, Ramsey SD. *Journal of the National Cancer Institute*, Jun 8;115(6):703-711,2023.
<https://pubmed.ncbi.nlm.nih.gov/36946291/>

S1204 Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation. Vaidya R, Unger J, Loomba R, Hwang J, Chugh R, Tincopa M, Arnold K, Hershman D, Ramsey S. Accepted 2023.

S1400I Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, Bazhenova L, Herbst R, Hershman D, Unger J. *JCO Clinical Cancer Informatics*, Apr;7:e2200165,2023. [see also Lung Committee]
<https://pubmed.ncbi.nlm.nih.gov/37084329/>

S1415CD Intervention non-adherence in The TrACER (S1415CD) study, a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing. Hershman DL, Bansal A, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Sullivan S, Lyman G, Ramsey S. Accepted 2023.

S1912CD Assessment of Financial Screening and Navigation Capabilities at NCI Community Oncology Clinics. Bell-Brown A, Watabayashi K, Delaney D, Carlos RC, Langer SL, Unger JM, Vaidya RR, Darke AK, Hershman DL, Ramsey SD, Shankaran V. *JNCI Cancer Spectr*. Aug 10;pkad055. doi: 10.1093/jncics/pkad055. Online ahead of print, 2023.
<https://pubmed.ncbi.nlm.nih.gov/37561111/>

Multiple Studies The Medicaid Expansion of the Affordable Care Act and the Participation of Patients with Medicaid in Cancer Clinical Trials. Unger J, Xiao H, Vaidya R, LeBlanc M, Hershman DL. *JAMA Onco*. Aug 17;e232800. doi: 10.1001/jamaoncol.2023.2800. Online ahead of print, 2023.
<https://pubmed.ncbi.nlm.nih.gov/37590003/>

Do I Know You? Patient Privacy and Consent in the Age of Social Media. Sommers J, Mercurio A. *JCO Oncol Pract*. Feb;19(2):72-73, 2023.
<https://pubmed.ncbi.nlm.nih.gov/36480776/>

Submitted Manuscripts

S1415CD Impact of Treatment Experience on Patient Knowledge of Colony Stimulating Factors Among Patients Receiving Cancer Chemotherapy: Evidence from S1415CD, A Large Pragmatic Trial. Lyman G, Bansal A, Sullivan S, Arnold K, Barlow W, Hershman D, Lad T, Ramsey S. Submitted 2023.

CANCER SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

IBC48 Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruiz-Borrego M, Moore HCF, Saunders C, Bjelic-Radiscic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. *N Engl J Med*. May 4;388(18):1645-1656, 2023. [see also Breast Committee]
<https://pubmed.ncbi.nlm.nih.gov/37133584/>

Submitted Manuscripts

None this cycle

PALLIATIVE AND END OF LIFE CARE COMMITTEE

Published/Accepted Manuscripts

S1316 Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Krouse RS, Anderson GL, Arnold KB, Thomson CA, Nfonsam VN, Al-Kasspoles, Walker JL, Sun V, Alvarez Secord A, Han ES, Leon-Takahashi AM, Isla-Ortiz D, Rodgers P, Hendren S, Sanchez Salcedo M, Laryea JA, Graybill WS, Flaherty DC, Mogal H, Miner TJ, Pimiento JM, Kitano M, Badgwell B, Whalen G, Lamont JP, Guevara OA, Senthil, Summer MS, Dewdney SB, Silberfein E, Wright JD, Friday B, Fahy B, Sathyanarayana SA, O'Rourke M, Bakitas M, Sloan J, Grant M, Deutsch GB, Deneve JL. *Lancet Gastroenterol Hepatol* Aug 1;S2468-1253(23)00191-7.
<https://pubmed.ncbi.nlm.nih.gov/37541263/>

None Feasibility and Acceptability of an Online Intervention to Enhance Hopefulness Among Oncology Professionals. Corn BC,

Publication List by Committee

Feldman DB, Subbiah IM, Corn PD, Bakitas MA, Krouse RS, Hudson MF, Fowler LA, Fraser V, Siegal C, Agarwal R, Ge JL, Parajuli J, Myers JS, O'Rourke MA. *JNCI Cancer Spectrum*, May 2;7(3):pkad030, 2023. <https://pubmed.ncbi.nlm.nih.gov/37104744/>

Submitted Manuscripts

S1820 Baseline Characteristics and Recruitment for SWOG S1820: Altering Intake, Managing Bowel Symptoms in Survivors of Rectal Cancer (AIMS-RC). Sun V, Thomson C, Crane T, Arnold K, Guthrie K, Freylerlythe S, Braun-Inglis C, Jones L, Carmichael J, Messick C, Flaherty D, Ambrale S, Cohen S, Krouse R. Submitted 2023.

PREVENTION AND EPIDEMIOLOGY COMMITTEE

Published/Accepted Manuscripts

S0000/Other Application of Mendelian randomization to explore the causal role of the human gut microbiome in colorectal cancer. Hatcher C, Richenberg G, Waterson S, Nguyen LH, Joshi AD, Carreras-Torres R, Moreno V, Chan AT, Gunter M, Lin Y, Qu C, Song M, Casey G, Figueiredo JC, Gruber SB, Hampe J, Hampel H, Jenkins MA, Keku TO, Peters U, Tangen CM, Wu AH, Hughes DA, Rühlemann MC, Raes J, Timpson NJ, Wade KH. *Sci Rep*. Apr 12;13(1):5968. doi: 10.1038/s41598-023-31840-0, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37045850/>

S0000/Other Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: Mendelian randomization. King SD, Veliginti S, Brouwers MCGJ, Ren Z, Zheng W, Setiawan VW, Wilkens LR, Shu XO, Arslan AA, Beane Freeman LE, Bracci PM, Canzian F, Du M, Gallinger SJ, Giles GG, Goodman PJ, Haiman CA, Kogevinas M, Kooperberg C, Le Marchand L, Neale RE, Visvanathan K, White E, Albanes D, Andreotti G, Babic A, Berndt SI, Brais LK, Brennan P, Buring JE, Rabe KG, Bamlet WR, Chanock SJ, Fuchs CS, Gaziano JM, Giovannucci EL, Hackert T, Hassan MM, Katzke V, Kurtz RC, Lee IM, Malats N, Murphy N, Oberg AL, Orlow I, Porta M, Real FX, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin BM, Duell EJ, Li D, Hung RJ, Perdomo S, McCullough ML, Freedman ND, Patel AV, Peters U, Riboli E, Sund M, Tjønneland A, Zhong J, Van Den Eeden SK, Kraft P, Risch HA, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Antwi SO. *Cancer Epidemiol Biomarkers Prev*. 2023 Jun 23:EPI-23-0453. doi: 10.1158/1055-9965.EPI-23-0453. Online ahead of print.

<https://pubmed.ncbi.nlm.nih.gov/37351909/>

S0000/Other Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not

Lewis Antigen (FUT3) Genotype. Kim J, Yuan C, Amundadottir L, Wolpin B, Klein A, Risch H, Kraft P [Pancreatic Cancer Consortium – PJ Goodman]. *Cancer Epidemiol Biomarkers Prev* Jun 21:EPI-23-0009. doi: 10.1158/1055-9965.EPI-23-0009. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37342060/>

S0000/Other A genetic locus within the FMN1/GREM1 gene region interacts with body mass index in colorectal cancer risk. Aglago EK, Kim AE, Lin Y, Qu C, Evangelou M, Ren Y, Morrison J, Albanes D, Arndt V, Barry EL, Baurley JW, Berndt SI, Bien SA, Bishop DT, Bouras E, Brenner H, Buchanan DD, Budiarto A, Carreras-Torres R, Casey G, Cenggoro TW, Chan AT, Chang-Claude J, Chen X, Conti DV, Devall M, Díez-Obrero V, Dimou N, Drew D, Figueiredo JC, Gallinger S, Giles GG, Gruber SB, Gsur A, Gunter MJ, Hampel H, Harlid S, Hidaka A, Harrison TA, Hoffmeister M, Huyghe JR, Jenkins MA, Jordahl K, Joshi AD, Kawaguchi ES, Keku TO, Kundaje A, Larsson SC, Le Marchand L, Lewinger JP, Li L, Lynch BM, Mahesworo B, Mandic M, Obón-Santacana M, Moreno V, Murphy N, Nan H, Nassir R, Newcomb PA, Ogino S, Ose J, Pai RK, Palmer JR, Papadimitriou N, Pardamean B, Peoples AR, Platz EA, Potter JD, Prentice RL, Rennert G, Ruiz-Narvaez E, Sakoda LC, Scacheri PC, Schmit SL, Schoen RE, Shcherbina A, Slattery ML, Stern MC, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Tian Y, Ulrich CM, van Duijnhoven FJB, Van Guelpen B, Visvanathan K, Vodicka P, Wang J, White E, Wolk A, Woods MO, Wu AH, Zemlianskaia N, Hsu L, Gauderman WJ, Peters U, Tsilidis KK, Campbell PT. *Cancer Res*. May 30;CAN-22-3713. doi: 10.1158/0008-5472.CAN-22-3713. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37249599/>

S0000/Other Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmidt S, Albanes D, Platz E, Lenz H-J, Tangen C, Gruber S, Tomlinson I, Zheng W, Dunlop M, Houlston R, Peters. *Nat Genet*. Jan;55(1):89-99, 2023.

<https://pubmed.ncbi.nlm.nih.gov/36539618/>

S0000/Other Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response. Carreras-Torres R, Kim AE, Lin Y, Díez-Obrero V, Bien SA, Qu C, Wang J, Dimou N, Aglago EK, Albanes D, Arndt V, Baurley JW, Berndt SI, Bézieau S, Bishop DT, Bouras E, Brenner H, Budiarto A, Campbell PT, Casey G, Chan AT, Chang-Claude J, Chen X, Conti DV, Dampier CH, Devall MAM, Drew DA, Figueiredo JC, Gallinger S, Giles GG, Gruber SB, Gsur A, Gunter MJ, Harrison TA, Hidaka A, Hoffmeister M, Huyghe JR, Jenkins MA, Jordahl KM, Kawaguchi E, Keku TO, Kundaje A, Le Marchand L, Lewinger JP, Li L, Mahesworo B,

Publication List by Committee

Morrison JL, Murphy N, Nan H, Nassir R, Newcomb PA, Obón-Santacana M, Ogino S, Ose J, Pai RK, Palmer JR, Papadimitriou N, Pardamean B, Peoples AR, Pharoah PDP, Platz EA, Rennert G, Ruiz-Narvaez E, Sakoda LC, Scacheri PC, Schmit SL, Schoen RE, Shcherbina A, Slattery ML, Stern MC, Su YR, Tangen CM, Thomas DC, Tian Y, Tsilidis KK, Ulrich CM, van Duijnhoven FJB, Van Guelpen B, Visvanathan K, Vodicka P, Cenggoro TW, Weinstein SJ, White E, Wolk A, Woods MO, Hsu L, Peters U, Moreno V, Gauderman WJ. *Cancer Epidemiol Biomarkers Prev.* 2023 Mar 6;32(3):315-328. doi: 10.1158/1055-9965.EPI-22-0763

<https://pubmed.ncbi.nlm.nih.gov/36576985/>

S0000/Other Probing the diabetes and colorectal cancer relationship using gene - environment interaction analyses. Dimou N, Kim AE, Flanagan O, Murphy N, Diez-Obrero V, Shcherbina A, Aglago EK, Bouras E, Campbell PT, Casey G, Gallinger S, Gruber SB, Jenkins MA, Lin Y, Moreno V, Ruiz-Narvaez E, Stern MC, Tian Y, Tsilidis KK, Arndt V, Barry EL, Baurley JW, Berndt SI, Bézieau S, Bien SA, Bishop DT, Brenner H, Budiarto A, Carreras-Torres R, Cenggoro TW, Chan AT, Chang-Claude J, Chanock SJ, Chen X, Conti DV, Dampier CH, Devall M, Drew DA, Figueiredo JC, Giles GG, Gsur A, Harrison TA, Hidaka A, Hoffmeister M, Huyghe JR, Jordahl K, Kawaguchi E, Keku TO, Larsson SC, Le Marchand L, Lewinger JP, Li L, Mahesworo B, Morrison J, Newcomb PA, Newton CC, Obón-Santacana M, Ose J, Pai RK, Palmer JR, Papadimitriou N, Pardamean B, Peoples AR, Pharoah PDP, Platz EA, Potter JD, Rennert G, Scacheri PC, Schoen RE, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Ulrich CM, Um CY, van Duijnhoven FJB, Visvanathan K, Vodicka P, Vodickova L, White E, Wolk A, Woods MO, Qu C, Kundaje A, Hsu L, Gauderman WJ, Gunter MJ, Peters U. *Br J Cancer.* 2023 Jun 26. doi: 10.1038/s41416-023-02312-z. Online ahead of print.

<https://pubmed.ncbi.nlm.nih.gov/37365285/>

S0000/S9217/Other Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S, Mucci LA, Hunter DJ, Penney KL, Tangen CM, Hamilton RJ, Parent MÉ, Stanford JL, Koutros S, Wolk A, Sørensen KD, Blot WJ, Yeboah ED, Mensah JE, Lu YJ, Schaid DJ, Thibodeau SN, West CM, Maier C, Kibel AS, Cancel-Tassin G, Menegaux F, John EM, Grindedal EM, Khaw KT, Ingles SA, Vega A, Rosenstein BS, Teixeira MR; NC-LA PCaP Investigators; Kogevinas M, Cannon-Albright L, Huff C, Multigner L, Kaneva R, Leach RJ, Brenner H, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Neuhausen

SL, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, De Ruyck K, Xu J, Razack A, Teo SH; Canary PASS Investigators; Newcomb LF, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Castelao JE, Townsend PA, Crawford DC, Petrovics G, Casey G, Roobol MJ, Hu JF, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S, Mucci LA, Hunter DJ, Penney KL, Tangen CM, Hamilton RJ, Parent MÉ, Stanford JL, Koutros S, Wolk A, Sørensen KD, Blot WJ, Yeboah ED, Mensah JE, Lu YJ, Schaid DJ, Thibodeau SN, West CM, Maier C, Kibel AS, Cancel-Tassin G, Menegaux F, John EM, Grindedal EM, Khaw KT, Ingles SA, Vega A, Rosenstein BS, Teixeira MR; NC-LA PCaP Investigators; Kogevinas M, Cannon-Albright L, Huff C, Multigner L, Kaneva R, Leach RJ, Brenner H, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Neuhausen SL, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, De Ruyck K, Xu J, Razack A, Teo SH; Canary PASS Investigators; Newcomb LF, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Castelao JE, Townsend PA, Crawford DC, Petrovics G, Casey G, Roobol MJ, Hu JF, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB. *Am J Hum Genet.* Jul 6;110(7):1200-1206, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37311464/>

S0000/S9217/Other Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. Chen F, Madduri RK, Rodriguez AA, Darst BF, Chou A, Sheng X, Wang A, Shen J, Saunders EJ, Rhie SK, Bensen JT, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Wang Y, Berndt SI, Huff CD, Yeboah ED, Tettey Y, Lachance J, Tang W, Rentsch CT, Cho K, McMahon BH, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Patel AV, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas CM, Stern MC, Kote-Jarai Z, Govindasami K, Cook MB, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann TJ, Drake BF, Hu JJ, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Idowu MO, Popoola O, Adebisi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Diop H, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJ, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Preuss MH, Loos RJ, Gundell SM, Wan P, Mohler JL, Fontham ET, Smith GJ,

Publication List by Committee

Taylor JA, Srivastava S, Eeles RA, Carpten JD, Kibel AS, Multigner L, Parent MÉ, Menegaux F, Cancel-Tassin G, Klein EA, Andrews C, Rebbeck TR. *Eur Urol*. Jul;84(1):13-21. doi: 10.1016/j.eururo.2023.01.022. Epub 2023 Mar 3, 2023.

<https://pubmed.ncbi.nlm.nih.gov/36872133/>

S0000/S9217 Genetically Adjusted PSA Levels for Prostate Cancer Screening. Kachuri L, Hoffmann T, Jiang Y, Berndt S, Shelley J, Schaffer K, Machiela M, Freedman N, Huang W, Li S, Easterlin R, Goodman P, Till C, Thompson I, Lilja H, Van Den Eeden S, Chanock S, Haiman C, Conti D, Klein R, Mosley J, Graff R, Witte J. *Nature Medicine*. Jun;29(6):1412-1423, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37264206/>

Submitted Manuscripts

S0000/Other Shedding light on the association between genetically-defined BMI and early-onset colorectal cancer in a pooled analysis [Brief Communication]. Archambault A, Gruber S, Le Marchand L, Hsu L, Peters U, Hayes R, on behalf of the Colorectal Transdisciplinary (CORECT) Study, the Colon Cancer Family Registry (CCFR), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) [P Goodman, C Tangen, GECCO collaborators]. Under review, 2023.

S0000/S9217/Other A prostate cancer susceptibility PSA variant that confers lower risk is also associated with more aggressive disease and poor survival. Srinivasan S, Kryza T, Bock N, Stephens C, Dong Y, Panchadsaram J, Moya L, Rohl J, Perry-Keene J, Buzacott K, Gago M, Schleutker J, Maier C, Muir K, Tangen C, Gronberg H, Pashayan N, Albanes D, Wolk A, Eles R, Clements J, Batra J. Under review, 2023.

SYMPTON CONTROL AND QUALITY OF LIFE COMMITTEE

Published/Accepted Manuscripts

S0221 Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in White and Black patients in SWOG S0221. Chen C, Zirpoli G, McCann S, Barlow W, Budd GT, Puzstai L, Henry NL, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Accepted 2023. [see also Breast Committee]

Submitted Manuscripts

None this cycle

DIGITAL ENGAGEMENT COMMITTEE

Published/Accepted Manuscripts

N/A Crisis of the clinical trials staff attrition following the COVID-19 pandemic. [Editorial] Sun G, Dizon D, Szczepanek C, Petrylak D, Sparks

D, Tangen C, Lara P, Thompson I, Blanke CD. *JCO Oncology Practice*. Jun 7;OP2300152. doi: 10.1200/OP.23.00152. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37285550/>

Submitted Manuscripts

None this cycle

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

G0182 The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. Sia TY, Tew WP, Purdy C, Chi DS, Menzin AW, Lovecchio JL, Bookman MA, Cohn DE, Teoh DG, Friedlander M, Bender D, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray HJ, Secord AA, Van Le L, Lichtman SM. *Gynecol Oncol*. Jun;173:130-137, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37148580/>

Submitted Manuscripts

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Salivary Gland Tumor Cohort. Chae Y, Sun R, Patel S, Giles F, Ohr J, Worden F, Suga J, Naing A, Cohen E, Wallace J, Fenton S, Il-Young Chung L, Kang H, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Othus M, Blanke CD, Kurzrock R. Submitted 2023.

EXECUTIVE COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

C/S80405 Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. *JCO Precision Oncology*. Chowdhury S, Gupta R, Millstein J, Lin K, Haridas V, Zeineddine MA, Parseghian C, Lenz HJ, Kopetz S, Shen JP. *JCO Precis Oncol*. Jul;7:e2200422. doi: 10.1200/PO.22.00422, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37487150/>

Publication List by Committee

C/S80702 Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance). Lee S, Ma C, Shi Q, Meyers J, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, O'Reilly EM, Shields AF, Meyerhardt JA. *Br J Cancer*. Aug;129(2):283-290, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37179438/>

C/S80702 Association between physical activity and the time course of cancer recurrence in stage III colon cancer. Brown JC, Ma C, Shi Q, Niedzwiecki D, Zemla T, Couture F, Kuebler P, Kumar P, Hopkins JO, Tan B, Krishnamurthi S, O'Reilly EM, Shields AF, Meyerhardt JA. *Br J Sports Med*. Aug;57(15):965-971, 2023.

<https://pubmed.ncbi.nlm.nih.gov/36878665/>

C/S80702 Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance). Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, Zemla T, Cheng E, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Goldberg RM, Venook A, Blanke C, Shields AF, O'Reilly EM, Meyerhardt JA, Ng K. *Clin Cancer Res*. Jul 14;29(14):2621-2630, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37289007/>

C/S80702/Other Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, André T, Papamichael D, Taieb J. *J Clin Oncol*. Feb 1;41(4):803-815, 2023.

<https://pubmed.ncbi.nlm.nih.gov/36306483/>

E2211 Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. *J Clin Oncol*. Mar 1;41(7):1359-1369, 2023

<https://pubmed.ncbi.nlm.nih.gov/36260828/>

N1048 Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D. *J Clin Oncol*. Jul 20;41(21):3724-3734, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37270691/>

N1048 Preoperative Treatment of Locally Advanced Rectal Cancer. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. *N Engl J Med*. Jul 27;389(4):322-334, 2023

<https://pubmed.ncbi.nlm.nih.gov/37272534/>

N9741 Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. McGarrath P, Hubbard J, Novotny PJ, Branda ME, Sargent DS, Morton RF, Fuchs CS, Benson AB, Williamson SK, Findlay BP, Alberts SR, Goldberg RM, Sloan JA. *Cancer Control*. Jan-Dec;30:10732748231185047, 2023

<https://pubmed.ncbi.nlm.nih.gov/37339926/>

Submitted Manuscripts

S0809 The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG S0809. Horowitz D, Colby S, Gholami S, Guthrie KA, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Chiorean E, Rocha F, Ahmad S, Ahmad S, Kachnic L. Under review 2023.

S1505 Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Cloyd J, Colby S, Guthrie KA, Lowy A, Chiorean E, Philip P, Sohal D, Ahmad S. Submitted 2023.

S1505 Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma: Analysis from SWOG S1505 [Brief Report]. Sohal D, Boutin R, Lenchik L, Kim J, Beg S, Wang-Gillam A, Wade J, Guthrie KA, Chiorean E, Ahmad S, Lowy A, Philip P, Chang V. Submitted 2023.

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Submitted 2023.

GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

Publication List by Committee

S0931 Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Ryan CW, Tangen C, Heath E, Stein M, Meng M, Alva A, Pal S, Puzanov I, Clark J, Choueiri T, Agarwal N, Uzzo R, Haas N, Synold T, Plets M, Vaishampayan U, Shuch B, Thompson IM, Lara PN. *Lancet*. Jul 28;S0140-6736(23)00913-3. doi: 10.1016/S0140-6736(23)00913-3. Online ahead of print.

<https://pubmed.ncbi.nlm.nih.gov/37524096/>

S1216 Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel. Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D, Vogelzang N, Thompson I, Agarwal N. *European Urology*. Apr 19;S0302-2838(23)02715-X. doi: 10.1016/j.eururo.2023.03.036. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37085425/>

S1216 Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain M, Quinn D, Lara P, Thompson I, Agarwal N. *JAMA Netw Open*. 2023 Aug 1;6(8):e2326546. doi: 10.1001/jamanetworkopen.2023.26546.

<https://pubmed.ncbi.nlm.nih.gov/37526936/>

S1314 Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Lu Y-T, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. *European Urology Oncology*. Apr 20;:S2588-9311(23)00074-3, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37087309/>

S1314 Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey, Theodorescu D, Goldkorn A, Milowsky M, Bangs R, MacVicar G, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Jr, Lerner SP. *European Urology*. Jul 4; S0302-2838(23)02945-7, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37414705/>

S1605 Phase II Trial of Atezolizumab in BCG-Unresponsive High Risk Non-Muscle Invasive Bladder Cancer: SWOG S1605. Black P, Tangen C, Singh P, McConkey D, Lucia MS, Lowrance WT, Koshkin V, Stratton

K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson, IM, Lerner SP. *Eur Urol*. Aug 16;S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.08.004. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37596191/>

A031201 Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. *J Clin Oncol*. Jun 20;41(18):3352-3362, 2023.

<https://pubmed.ncbi.nlm.nih.gov/36996380/>

Submitted Manuscripts

S1216 Baseline circulating tumor cell count as a prognostic marker of overall survival in metastatic hormone sensitive prostate cancer (SWOG S1216). Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Jr., Hussain M, Quinn D, Dorff T, Thompson I, Jr, Agarwal N. Submitted 2023.

S1216 Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide. Parikh M, Tangen C, Hussain M, Gupta S, Jo Y, Callis S, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynsk R, Bryce A, Lin D, Quinn D, Thompson I, Lerner SP, Dorff T, Lara P, Agarwal N. Submitted 2023.

S1314 Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy (NAC) for Localized, Muscle-Invasive Bladder Cancer (SWOG S1314; NCT02177695). Lerner S, McConkey DJ, Tangen C, Meeks JJ, Flaig T, Hua X, Daneshmand S, Alva A, Lucia MS, Theodorescu D, Goldkorn A, Milowsky M, Choi W, Bangs R, Gustafson D, Plets M, Thompson IM. Submitted 2023.

E3805 Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. Submitted 2023.

Publication List by Committee

IMMUNOTHERAPEUTICS COMMITTEE

Published/Accepted Manuscripts

MyeloMatch/IMATCH/Other The new NCI precision medicine trials. Harris L, Blanke CD, Erba H, Ford J, Gray R, LeBlanc M, Hu-Leiskovan S, Litzow M, Lunger S, Meric-Bertram F, O'Dwyer P, Othus M, Politi K, Shepherd L, Allegra C, Chen H, Ivy S, Korde L, Little R, McShane L, Moscow J, Patton D, Thurin M, Yee L, Doroshow J. *Clin Cancer Res* Aug 2;CCR-23-0917. doi: 10.1158/1078-0432.CCR-23-0917. Online ahead of print, 2023. [see also Leukemia Committee] <https://pubmed.ncbi.nlm.nih.gov/37531248/>

Submitted Manuscripts

None this cycle

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

MyeloMatch/IMATCH/Other The new NCI precision medicine trials. Harris L, Blanke CD, Erba H, Ford J, Gray R, LeBlanc M, Hu-Leiskovan S, Litzow M, Lunger S, Meric-Bertram F, O'Dwyer P, Othus M, Politi K, Shepherd L, Allegra C, Chen H, Ivy S, Korde L, Little R, McShane L, Moscow J, Patton D, Thurin M, Yee L, Doroshow J. *Clin Cancer Res* Aug 2;CCR-23-0917. doi: 10.1158/1078-0432.CCR-23-0917. Online ahead of print, 2023. [see also Immunotherapeutics Committee] <https://pubmed.ncbi.nlm.nih.gov/37531248/>

A041202 Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, Nelson AM, Newcomb RA, Rice J, Lavoie MW, Ritchie CS, Bartlett N, Stephens DM, Ding W, Owen C, Stone R, Ruppert AS, Mandrekar SJ, Byrd JC, El-Jawahri A, Le-Rademacher J, Rosko A. *J Geriatr Oncol*. Jul;14(6):101538, 2023. <https://pubmed.ncbi.nlm.nih.gov/37329769/>

S0106/Other Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, ECOG analysis. Zarnegar-Lumley S, Alonzo T, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti AR, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer KM, Tallman MS, Litzow MR, Atallah E, Cooper TM, Aplenc R, Abdel-Wahab OI, Gamis AS, Luger SM, Erba HP, Levine RL, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. *Blood Adv*. 2023 Jun 2;bloodadvances.2022008282. doi: 10.1182/bloodadvances.2022008282. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/37267439/>

Multiple Studies* Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network. Termini C, Moseley A, Othus M, Appelbaum F, Chauncey T, Erba H, Fang M, Lee S, Naru J, Pogosova-Agadjanyan E, Radich J, Willman C, Wu F, Meshinchi S, Stirewalt D. *Haematologica*. Apr 6. doi: 10.3324/haematol.2023.282733. Online ahead of print, 2023. [*S0106,S0112,S9031,S9333] <https://pubmed.ncbi.nlm.nih.gov/37021537/>

Multiple Studies* Long Non-coding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Ferrar J, Smith J, Othus M, Huang B, Wang Y, Ries R, Hylkema T, Pogosova-Agadjanyan E, Leonti A, Shaw T, Triche T, Gamis A, Aplenc R, Kolb E, Ma X, Stirewalt D, Alonzo T, Meshinchi S. *Journal of Clinical Oncology* Jun 1;41(16):2949-2962, 2023. [S0106,S0112,S9031,S9333,OTHER] <https://pubmed.ncbi.nlm.nih.gov/36795987/>

Multiple Studies* Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients. Pogosova-Agadjanyan E, Hua X, Othus M, Appelbaum F, Chauncey T, Erba H, Fitzgibbon M, Godwin J, Jenkins I, Fang M, Lee SC, Moseley A, Naru J, Radich J, Smith JL, Willborg B, Willman C, Wu F, Meshinchi S, Stirewalt D. *Biomarker Research*, Mar 16;11(1):31, 2023. [*S0106,S0112,S9031,S9333] <https://pubmed.ncbi.nlm.nih.gov/36927800/>

Submitted Manuscripts

S1203 Standard versus high-dose cytarabine with or without vorinostat for AML. Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland SA, Litzow MR, Savoie M, Medeiros B, Sekeres M, Lin TL, Uy G, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba HP. Resubmitted 2023.

LUNG COMMITTEE

Published/Accepted Manuscripts

LUNGMAP Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, Neal J, Leal T, Patel J, Dragnev K, Waqar S, Edelman M, Sigal E, Adam S, Malik S, Blanke C, LeBlanc M, Kelly K, Gray J, Redman M. Accepted 2023.

Publication List by Committee

S1400I Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for advanced squamous cell lung cancer patients from the phase III SWOG Lung-MAP S1400I trial. *Clinical Cancer*. Parra E, Duose D, Zhang J, Redman M, Lazcano Segura R, Marques-Puibelli M, Fernandez C, Zhang B, Lindsay J, Moravec R, Kannan K, Luthra R, Al-atrash G, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C, Manyam G, Zhang J, Song X, Rojas F, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Van Nostrand D, Provencher J, Yu J, Cerami E, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Biswas R, Kim-Schulze S, Kelly K, Gnajatic S. Accepted 2023.

S1400I Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, Bazhenova L, Herbst R, Hershman D, Unger J. *JCO Clinical Cancer Informatics* Apr;7:e2200165, 2023. [see also CCD Committee] <https://pubmed.ncbi.nlm.nih.gov/37084329/>

S1507 Phase II study of docetaxel and trametinib in patients with G12C and non-G12C KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT). Gadgeel S, Miao J, Riess J, Mack P, Gerstner G, Burns T, Taj A, Akerley W, Dragnev K, Laudi N, Moon J, Gray JE, Gandara DR, Kelly KL. *Cancer Research* May 26;CCR-22-3947. doi: 10.1158/1078-0432.CCR-22-3947. Online ahead of print, 2023. <https://pubmed.ncbi.nlm.nih.gov/37233987/>

C140503 Lobectomy, segmentectomy or wedge resection for peripheral clinical T1aNO non-small cell lung cancer: a post-hoc analysis of CALGB 140503 (Alliance). Altorki N, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Stinchcombe TE. *J Thorac Cardiovasc Surg*. Jul 18:S0022-5223(23)00612-8, 2023. <https://pubmed.ncbi.nlm.nih.gov/37473998/>

Submitted Manuscripts

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer: correlative analysis of SWOG S0819 phase III randomized trial. Derclé L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted 2023.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

S0016 Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma. Burack WR, Li H, Adlowitz D, Spence J, Rimsza L, Shadman M, Spier C, Kaminski M, Leonard J, LeBlanc M, Smith S, Friedberg J. *Blood Advances, Blood Adv*. Jun 28: bloodadvances.2022009467. doi: 10.1182/bloodadvances.2022009467. Online ahead of print.2023. <https://pubmed.ncbi.nlm.nih.gov/37379264/>

CTSU 9177 Prognostic Factors for Adult Burkitt Lymphoma Patients Treated with Dose-Adjusted EPOCH-R. Lakhota R, Kieron D, Abramson J, Brian K, Powell B, Melani C, Lucas N, Steinberg S, Friedberg JW, Kahl B, Little R, Bartlett N, Noy A, Wilson W, Roschewski M. *Blood Adv*. Jun 30: bloodadvances.2023010223. doi: 10.1182/bloodadvances.2023010223. Online ahead of print, 2023. <https://pubmed.ncbi.nlm.nih.gov/37389844/>

C50303 Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis. Torka P, Pederson L, Knopp M, Poon D, Zhang J, Kahl B, Higley H, Kelloff G, Friedberg JW, Schwartz L, Wilson W, Leonard J, Bartlett N, Schoder H, Ruppert A. *Cancer Medicine* Apr;12(7):8211-8217, 2023. <https://pubmed.ncbi.nlm.nih.gov/36799072/>

Multiple Studies* The Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Development and Validation of a Clinical Prediction Model from the HoLISTIC Consortium. Rodday A, Parsons S, Upshaw J, Friedberg JW, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link B, Mou E, Savage K, Zinzani P, Maurer M, Evens A. *Journal of Clinical Oncology* Apr 10;41(11):2076-2086, 2023. [*S0816, OTHER] <https://pubmed.ncbi.nlm.nih.gov/36495588/>

Submitted Manuscripts

C51101 Myeloablative Versus Non-Myeloablative Consolidation for Newly Diagnosed Primary CNS Lymphoma: Results of Alliance 51101. Batchelor T, Giri S, Ruppert A, Geyer S, Smith S, Mohile N, Swinnen L, Friedberg JW, Kahl B, Bartlett N, Hsi E, Cheson B, Wagner-Johnston N, Nayak L, Leonard J, Rubenstein J. Submitted 2023.

Publication List by Committee

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S1404 Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Eljilany I, Noor A, Paravathaneni M, Yassine I, Lee SJ, Othus M, Moon J, Kirkwood JM, Sondak VK, Ribas A, Grossmann KF, Tarhini AA. *Cancers (Basel)*. Apr 29;15(9):2561, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37174027/>

S1616 Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. VanderWalde A, Bellasea S, Kendra K, Khushalani NI, Campbell KM, Scumpia PP, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong T-G, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medini E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Perez Garcilazo I, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. *Nature Medicine* Aug 17. doi: 10.1038/s41591-023-02498-y. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37592104/>

Submitted Manuscripts

S1221 A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers. Algazi AP, Moon J, Chmielowski B, Lo R, Lao C, Kendra K, Lewis K, Gonzalez R, Kim K, Godwin JE, Curti B, Latkovic-Taber M, Othus M, Ribas A. Submitted 2023.

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

S0226 Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, Dakhil SR, Tirumali NR, Galow J, Hortobagyi GN, Puzstai L, Mehta RS, Hayes DF, Kidwell KM, Henry NL, Barlow WE, Rae JM, Hertz DL. *Pharmacogenomics* Aug 24. doi: 10.2217/pgs-2023-0097. Online ahead of print, 2023.[see also Breast Committee]

<https://pubmed.ncbi.nlm.nih.gov/37615099/>

Submitted Manuscripts

None this cycle

